combination

By combining sulfonylureas with insulin modulators and aldosterone antagonists, the treatment challenges of stroke and neurodegenerative diseases have been addressed, achieving more effective neuroprotection and reduced reperfusion injury.

CN114423461BActive Publication Date: 2024-11-26GENESIS PHARMA SA
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN202080057768.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-09
Filing Date
2020-07-09
Publication Date
2024-11-26
Estimated Expiration
2040-07-09

AI Technical Summary

Technical Problem

Currently, there is a lack of effective pharmacological treatments for stroke, brain reperfusion injury, and neurodegenerative diseases. Existing treatments have not significantly improved prognosis and lack neuroprotective measures.

Method used

The combination of sulfonylureas and insulin modulators (such as glibenclamide and exenatide) and aldosterone antagonists (such as canlenate potassium) provides neuroprotection through synergistic effects for the treatment and prevention of stroke, cerebral reperfusion injury and neurodegenerative diseases.

Benefits of technology

This combination significantly improved neuroprotection and reduced reperfusion injury at lower doses than the recommended doses of each drug used alone, providing a more effective treatment and prevention measure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003505453870000091
    Figure BDA0003505453870000091
  • Figure BDA0003505453870000092
    Figure BDA0003505453870000092
  • Figure BDA0003505453870000093
    Figure BDA0003505453870000093
Patent Text Reader

Abstract

The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin regulator and (ii) an aldosterone antagonist, for example, the combination comprises (a) glibenclamide or a structural or functional analog thereof; and (b) at least one of the following components: (i) exenatide or a structural or functional analog thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analog thereof. The combination is suitable for treating stroke and other neurodegenerative disorders, and for treating and / or preventing ischemia and / or reperfusion injury of various important organs including the brain and heart. Other aspects of the present invention relate to pharmaceutical products and pharmaceutical compositions comprising the combination according to the present invention, and methods of using them for treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention provides a combination suitable for treating stroke and neurodegenerative disorders and for treating and / or preventing ischemia and / or reperfusion injury in various vital organs including the brain and heart.

[0002] Other aspects of the invention relate to pharmaceutical products and compositions comprising the combinations, and methods of treatment using the same. Background Art

[0003] Stroke is caused by a lack of blood flow to the brain (ischemic stroke) or by bleeding in the brain (hemorrhagic stroke), both of which lead to the death of brain cells. According to the World Health Organization, stroke caused approximately 6 million deaths in 2016, making it the second most important cause of death worldwide. According to the Global Burden of Disease study (Johnson CO et al., Lancet Neurol. 2019; 18: 439-58), there were 13.7 million new cases of stroke and 80.1 million active stroke cases worldwide in 2016. The high burden of stroke worldwide suggests that primary prevention strategies are neither widely implemented nor sufficiently effective. Guidelines for the control of acute ischemic stroke are available (Powers WJ et al., Stroke. 2018; 49: e46-e99). Interestingly, the guidelines conclude that there are currently no pharmacological or nonpharmacological treatments with proven neuroprotective properties that have demonstrated efficacy in improving outcomes after ischemic stroke, and therefore, no other neuroprotective agents are recommended. There are also guidelines for managing hemorrhagic stroke; however, these guidelines do not recommend treatments other than rehabilitation for managing neurodegenerative outcomes in hemorrhagic stroke (Hemphill JC 3rd et al., Stroke. 2015; 46: 2032-2060).

[0004] The above data clearly demonstrate that there is currently a lack of effective pharmacological treatments for ischemic or hemorrhagic stroke and that neuroprotective treatments are needed in stroke patients. Effective treatments for stroke-related reperfusion injury have the potential to provide neuroprotection. However, attempts to develop effective neuroprotective treatments for stroke patients based on reducing reperfusion injury have not been successful to date (Savitz SI et al., Stroke. 2017; 48: 3413-3419; Patel RAG et al., Prog Cardiovasc Dis. 2017; 59: 542-548). Previous studies in the field of cardioprotection and reperfusion injury have revealed the surprising discovery that combination therapies that are not suitable for the treatment of cardiovascular disorders can produce significant synergistic effects to prevent myocardial reperfusion injury if used at dose levels lower than those suitable for these other disorders (WO2017 / 077378; US10,172,914; Genesis Pharma SA).

[0005] Treatments that show neuroprotective effects are expected to be useful in treating neurodegenerative disorders. Neurodegenerative disorders are due to the progressive loss of structure or function of neurons, which ultimately leads to neuronal death. Neurodegenerative disorders include currently incurable diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and vascular dementia. Between 2007 and 2017, Alzheimer's disease showed the highest increase (46.7%) among neurological disorders worldwide, reaching 2.51 million deaths in 2017 (Roth GA et al., Lancet 2018; 392: 1736-88). In the same study, Parkinson's disease also showed a 38.3% increase, resulting in 340,600 deaths worldwide in 2017. The prevalence of amyotrophic lateral sclerosis per 100,000 population is 5.40 in Europe, 3.40 in the United States, and 2.34 in Asia (Marin B et al., Int J Epidemiol 2017; 46: 57-74). Huntington's disease is an inherited neurological disorder that is considered a rare disease, with a prevalence ranging from 0.4 in Asia to 7.3 in North America per 100,000 population (Rawlins MD. Neuro Paditiomicology. 2016; 46: 144-53). Vascular dementia is a dementia caused by problems with the blood supply to the brain, usually a series of mild strokes, leading to a progressive and worsening cognitive decline. The term refers to a syndrome consisting of a complex interaction of cerebrovascular disease and risk factors that lead to changes in brain structure due to strokes and lesions, and to changes in cognition. Vascular dementia is the second most common form of dementia after Alzheimer's disease (AD) in the elderly (Battistin L, (December 2010), Neurochemical Research 35, (12): 1933-8; "Vascular Dementia: A Resource List"). The prevalence of the disease is 1.5% in Western countries and about 2.2% in Japan. Vascular dementia accounts for 50% of all dementia in Japan, 20% to 40% of all dementia in Europe, and 15% of all dementia in Latin America. 25% of stroke patients develop new-onset dementia within one year of their stroke. One study found that in the United States, the prevalence of vascular dementia in all people over 71 years old was 2.43%, and another study found that the prevalence of dementia doubled every 5.1 years (Plassman BL, (2007), Neuroepithaliology. 29 (1-2); Jorm AF (November 1987), Acta Psychiatca Scandinavica. 76 (5): 465-79). Currently, there is no drug approved specifically for the prevention or treatment of vascular dementia.Currently approved treatments for Alzheimer's disease offer only modest benefits (Atri A. Med Clin North Am. 2019; 103: 263-293). Many pharmacological treatments are available to control the motor and non-motor symptoms of Parkinson's disease, but they are essentially symptomatic and ultimately induce dyskinesias, and none of them provide neuroprotection (Chaudhuri KR et al., Parkinsonism Relat Disord. 2016; 33 (Suppl 1): S2-S8). There are currently only two approved drugs that slow (although not much) the progression of amyotrophic lateral sclerosis (riluzole and edaravone), and there are no approved treatments for Huntington's disease.

[0006] Therefore, there is a clear need for additional and better treatments that provide neuroprotection, particularly in the context of treating stroke, cerebral reperfusion injury, and certain neurodegenerative diseases. Summary of the invention

[0007] The present invention provides combinations that are neuroprotective and suitable for preventing or treating cerebral reperfusion injury, stroke and other conditions / diseases that require neuroprotection. Advantageously, the presently claimed combinations and other aspects of the present invention provide more effective treatment methods and provide superior clinical results compared to treatment methods using single active drug formulations.

[0008] A first aspect relates to a combination comprising:

[0009] (a) sulfonylureas; and

[0010] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0011] A second aspect relates to a combination comprising:

[0012] (a) glibenclamide or a structural or functional analogue thereof; and

[0013] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0014] The third aspect relates to a pharmaceutical composition comprising:

[0015] (a) sulfonylureas; and

[0016] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist; and

[0017] A pharmaceutically acceptable carrier, diluent or excipient.

[0018] The fourth aspect relates to a pharmaceutical composition comprising:

[0019] (a) glibenclamide or a structural or functional analogue thereof; and

[0020] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof; and

[0021] A pharmaceutically acceptable carrier, diluent or excipient.

[0022] The fifth aspect relates to a pharmaceutical product comprising:

[0023] (a) sulfonylureas; and

[0024] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0025] The sixth aspect relates to a pharmaceutical product comprising:

[0026] (a) glibenclamide or a structural or functional analogue thereof; and

[0027] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0028] A seventh aspect relates to the following uses of the combination or pharmaceutical composition or pharmaceutical product as defined above: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative diseases, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs.

[0029] An eighth aspect relates to the following uses of the pharmaceutical product as defined above: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative diseases, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs, wherein the components are for simultaneous, sequential or separate administration.

[0030] The ninth aspect relates to a method for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs, the method comprising administering simultaneously, sequentially or separately to a subject in need thereof:

[0031] (a) sulfonylureas; and

[0032] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0033] The tenth aspect relates to a method for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs, the method comprising administering simultaneously, sequentially or separately to a subject in need thereof:

[0034] (a) glibenclamide or a structural or functional analogue thereof; and

[0035] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0036] The eleventh aspect relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs:

[0037] (a) sulfonylureas; and

[0038] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0039] A twelfth aspect relates to the use of the following substances in the manufacture of a drug for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs:

[0040] (a) glibenclamide or a structural or functional analogue thereof; and

[0041] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0042] A thirteenth aspect relates to the use of a combination for treating and / or preventing ischemia and / or reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0043] (a) sulfonylureas; and

[0044] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0045] A fourteenth aspect relates to the use of a combination for treating and / or preventing ischemia and / or reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0046] (a) glibenclamide or a structural or functional analogue thereof; and

[0047] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof. DETAILED DESCRIPTION

[0048] The preferred embodiments listed below are applicable to any of the above aspects of the invention, as appropriate.

[0049] As used herein, a structural analog, also called a chemical analog, is a compound that has a structure similar to another compound, but differs from the other compound in certain components. It may differ in one or more atoms, functional groups, or substructures, where the difference is replaced by other atoms, groups, or substructures. At least in theory, it is conceivable that structural analogs are formed from other compounds. Structural analogs are usually isoelectronic.

[0050] As used herein, a functional analog is a compound that has similar physical, chemical, biochemical or pharmacological properties as another compound. A functional analog is not necessarily a structural analog with a similar chemical structure.

[0051] Sulfonylurea

[0052] The combination of the present invention contains a sulfonylurea as an essential component.

[0053] Sulfonylureas are a class of oral hypoglycemic agents that are primarily used to control type 2 diabetes and certain forms of monogenic diabetes. Sulfonylureas lower blood glucose levels by stimulating the secretion of insulin from pancreatic β-cells. The primary target of sulfonylureas is the ATP-sensitive potassium (K) ATP ) channel sulfonylurea receptor (SUR1) subunit (Proks P et al., Diabetes. 2002; 51(Suppl 3): S368-76; Gribble FM and Reimann F. Diabetologia. 2003; 46: 875-891).

[0054] Sulfonylureas are traditionally divided into two generations, in line with the time of their introduction in the clinic, differing mainly in their disposition, which allows drugs belonging to the second generation to be administered less frequently (Sola D et al., Arch Med Sci. 2015; 11: 840-8):

[0055] The first generation includes chlorpropamide, tolbutamide, acetohexamide, amoxicillin, glycidylchloride, tolhexamide, metabolamide, and tolazamide; however, these are no longer used in clinical practice;

[0056] • The second generation includes glibenclamide (glyburide), gliprexa, gliclazide, glipizide, glimepiride, gliclazide, gliplimid, and glyburide. For some second generation sulfonylureas (gliclazide, glipizide), modified / extended release formulations exist.

[0057] When adequate control cannot be achieved with metformin alone, current guidelines recommend the use of second-generation sulfonylureas as second-line therapy in combination with metformin. If glycemic control cannot be achieved with a combination of two drugs, second-generation sulfonylureas can also be used in combination therapy with three drugs (Garber AJ et al., Endocr Pract. 2019; 25: 69-100; Inzucchi SE et al., Diabetes Care. 2015; 38: 140-9). The decision to use sulfonylureas should take into account patient characteristics and potential adverse events associated with sulfonylureas (Cordiner RLM, Pearson ER. Diabetes Obes Metab. 2019; 21: 761–771).

[0058] In a particularly preferred embodiment, the sulfonylurea is a Sur-1 receptor antagonist. Suitable Sur-1 receptor antagonists can be identified using known assays.

[0059] In a particularly preferred embodiment, the sulfonylurea is a SUR1-TRPM4 channel antagonist. Suitable SUR1-TRPM4 channel antagonists can be identified using known assays.

[0060] The present invention also encompasses structural or functional analogs of sulfonylureas, in particular structural or functional analogs of sulfonylureas that have been modified so as to increase the half-life of the formulation, such as conjugates of sulfonylureas.

[0061] In a preferred embodiment, the sulfonylurea is selected from the group consisting of glibenclamide (glyburide), gliprexa, gliclazide, glipizide, glimepiride, gliquidone, glislipide, and glyburide.

[0062] In a highly preferred embodiment, the sulfonylurea is selected from the group consisting of glibenclamide and structural and functional analogs thereof.

[0063] Preferably, the sulfonylurea is selected from the group consisting of acylhydrazone, sulfonamide and sulfonylthiourea derivatives of glibenclamide, glimepiride, glipizide and gliclazide.

[0064] In a preferred embodiment, the sulfonylurea is glimepiride, which has the structure shown below:

[0065]

[0066] In a preferred embodiment, the sulfonylurea is gliclazide, which has the structure shown below:

[0067]

[0068] In a preferred embodiment, the sulfonylurea is glipizide, which has the structure shown below:

[0069]

[0070] In a particularly preferred embodiment, the sulfonylurea is glibenclamide.

[0071] The systematic (IUPAC) name of glibenclamide is 5-chloro-N-[2-[4-(cyclohexylcarbamoyl-sulfamoyl)phenyl]ethyl]-2-methoxybenzamide (chemical formula is C 23 H 28 ClN3O5S), and a molecular weight of 494; it has the following chemical structure:

[0072]

[0073] The present invention also encompasses structural and functional analogs of glibenclamide, in particular structural and functional analogs of glibenclamide that have been modified so as to extend the half-life of the formulation, such as conjugates of glibenclamide.

[0074] Glyburide (also known as glyburide) is a sulfonylurea receptor-1 (Sur-1) receptor antagonist used as a hypoglycemic agent to treat diabetes. Glyburide is being developed as a treatment for reducing edema after brain injury, such as ischemic stroke, traumatic brain injury, and subarachnoid hemorrhage, but the results to date have been inconsistent (Wilkinson CM et al., PLoS One. 2019; 14: e0215952; Xu F et al., Brain Behav. 2019; 9(4): e01254; King ZA et al.; Drug Des Devel Ther. 2018; 12: 2539-2552). The present inventors investigated the role of gliburide as part of a combination therapy designed to reduce reperfusion injury and potentially produce neuroprotective effects.

[0075] Glibenclamide can be obtained as a generic product and is sold in many brands with a dosage of 1.25 mg, 2.5 mg and 5 mg, including Gliben-J, Daonil, Diabeta, Euglucon, Gilemal, Glidanil, Glybovin, Glynase, Maninil, Micronase and Semi-Daonil. Glibenclamide is taken orally as a tablet formulation (for adults) or as an oral suspension (for children) for the treatment of type 2 diabetes. The defined daily dose (DDD) of glibenclamide for the treatment of type 2 diabetes is 7 mg for micronized formulations and 10 mg for conventional formulations, and the micronized formulation has higher bioavailability. The defined daily dose (DDD) is the assumed average daily maintenance dose of the drug for the main indications of adults defined by the WHO Collaborating Center for Drug Statistics Methods. DDD is a unit of measurement and therefore does not necessarily reflect the recommended or prescribed daily dose. The therapeutic dose for individual patients and groups of patients will generally differ from the DDD because the therapeutic dose will be based on individual characteristics (e.g. age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations. The DDD value for glibenclamide was obtained from the WHO Collaborating Centre for Pharmaceutical Statistical Methods, (see https: / / www.whocc.no / atc_ddd_index / ?code=A10BB01&showdescription=yes). The usual starting dose of glibenclamide (micronized formulation) in initial treatment is 2.5 mg to 5 mg per day, and the usual maintenance dose is in the range of 1.25 mg to 20 mg per day, which can be given as a single dose or in divided doses, administered with breakfast or the first main meal (depending on the FDA label for Glyburide tablets). For a 70 kg adult, this corresponds to a maintenance dose of about 18 μg / kg to about 285 μg / kg.

[0076] Several studies in animal models have shown the protective effects of glibenclamide in inflammation-related injuries, including reducing adverse neuroinflammation and improving behavioral outcomes after central nervous system injury (Zhang G et al., Mediators Inflamm. 2017; 2017: 3578702) or ischemic and hemorrhagic stroke (Caffes N et al., Int J Mol Sci. 2015; 16: 4973-84). In a rat model of traumatic brain injury, glibenclamide was administered intraperitoneally at a loading dose of 10 μg / kg, followed by an infusion of 200 ng / hr for 7 days (Patel AD et al., J Neuropathol Exp Neurol. 2010; 69: 1177-90), while in a mouse model of traumatic brain injury, the dose of glibenclamide administered in three days after a controlled cortical impact injury was 10 μg (Xu ZM et al., J Neurotrauma. 2017; 34: 925-933). In a rodent model of cerebral ischemia and reperfusion injury, a 1 mg / kg dose of glibenclamide administered 10 minutes before reperfusion was shown to be effective (Abdallah DM et al., Brain Res. 2011; 1385: 257-62). In a rodent model of subarachnoid hemorrhage, glibenclamide was shown to be effective when administered intraperitoneally at a loading dose of 10 μg / kg and then infused at 200 ng / hr for 24 hours (Simard, JM et al., Journal of Cerebral Blood Flow and Metabolism. 2009; 29; 317-330) or one week (Tosun C et al., Stroke. 2013; 44: 3522-8). In a rat thromboembolic model of stroke, glibenclamide administered as a continuous infusion (75 ng / h) reduced brain edema, infarct volume, and mortality by 50% 7 days after middle cerebral artery occlusion, with the reduction in infarct volume associated with cortical sparing (Simard JM et al., Nat Med. 2006; 12: 433-40).Glibenclamide administered at a dose of 10 μg 2 hours before or after experimental intracerebral hemorrhage in mice was shown to reduce brain edema, disrupted BBB, and neurological deficits (Xu F et al., Brain Behav. 2019;9:e01254), and similar findings were obtained in another study (Jiang B et al., Transl Stroke Res. 2017;8:183-193), however, when intracerebral hemorrhage was produced by intrastriatal injection of collagenase, the widely used dose of glibenclamide that showed effectiveness in other studies (10 μg / kg loading dose followed by 200 ng / h for up to 7 days) was shown to be ineffective (Wilkinson CM et al., PLoS One. 2019;14(5):e0215952).

[0077] In some clinical trials, glibenclamide has also been shown to exert beneficial effects in stroke patients. In the Glyburide Advantage in Malignant Edema and Stroke (GAMES) clinical trial for patients with large hemispheric infarction, intravenous administration of glyburide (RP-1127) was performed as a 0.13 mg bolus intravenous injection within the first 2 minutes, followed by an infusion of 0.16 mg / h within the first 6 hours, and then 0.11 mg / h for the remaining 66 hours, and revealed promising findings on brain swelling (midline shift), MMP-9, functional prognosis, and mortality (King ZA et al., Drug Des Devel Ther. 2018; 12: 2539-2552). In an exploratory study of oral administration of glibenclamide to patients with acute hemispheric infarction, treatment was shown to be safe, but the treatment did not substantially improve functional outcomes at 6 months, although it was associated with less severe cerebral edema and a slight trend toward less severe disability, and death was observed (Huang K et al., Acta Neurol Scand. 2019 May 29). A retrospective analysis of data from diabetic patients who did not use sulfonylureas and those who used sulfonylureas during the days following acute ischemic stroke found a strong association between sulfonylurea treatment and improved survival, better functional independence, lower NIH stroke grade scores, and less hemorrhagic transformation (Kunte H et al., Ann Neurol. 2012; 72: 799-806).

[0078] The above preclinical and clinical findings may be related to the upregulation of UR1-TRPM4 channels after brain injury such as ischemia (Woo SK et al., J Biol Chem. 2013; 288: 3655-67; ​​Mehta RI et al., J Neuropathol Exp Neurol. 2015; 74: 835-49).

[0079] Neuroprotective effects of other sulfonylureas, such as the neuroprotective effect of gliclazide in animal models of ischemia and reperfusion injury (Tan F et al., Brain Res. 2014; 1560: 83-90), and protective effects in animal models of ischemia and reperfusion injury in other tissues, such as the protective effect of glimepiride on the myocardium (Nishida H et al., J Pharmacol Sci. 2009; 109: 251-6) have also been reported.

[0080] Some other drugs have insulin secretagogue effects similar to sulfonylureas; examples include meglitinides (e.g., repaglinide, nateglinide, and mitiglinide). In addition, other compounds, such as resveratrol, have been shown to bind to sulfonylurea receptors (Hambrock A et al., J Biol Chem. 2007; 282: 3347-56) and have neuroprotective effects in stroke and traumatic CNS injury (Lopez MS et al., Neurochem Int. 2015; 89: 75-82).

[0081] Studies by the applicant and described in more detail in the appended examples have shown that the administration of a sulfonylurea (e.g. glibenclamide) in combination with a second active substance, which is an aldosterone antagonist (e.g. potassium canrenoate) or an insulin regulator (e.g. exenatide), produces a neuroprotective effect even when the sulfonylurea is administered only in very low doses.

[0082] Insulin regulators

[0083] In one embodiment, the combination of the invention comprises, in addition to the sulfonylurea component described above, an insulin modulator.

[0084] As used herein, the term "insulin modulator" refers to an agent that can directly or indirectly increase or decrease insulin activity, which in turn can increase or decrease insulin-mediated physiological responses.

[0085] In one embodiment, the insulin modulator is selected from the group consisting of a GLP-1 agonist, a DPP-4 inhibitor, a PPAR agonist, insulin, and analogs thereof.

[0086] Examples of GLP-1 agonists include exenatide, lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265), and pharmaceutically acceptable salts thereof.

[0087] Examples of DPP-4 inhibitors include sitagliptin, vildagliptin, saxagliptin, linagliptin, alagliliptin, teneligliptin, alogliptin, trelagliptin, gemagliptin, dutogliptin and omagliliptin (MK-3102) and pharmaceutically acceptable salts thereof.

[0088] Examples of PPAR agonists include clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saxaglitazar, aleglitazar, moglitazar and tesaglitazar, and pharmaceutically acceptable salts thereof.

[0089] Examples of insulin analogs include insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine, and pharmaceutically acceptable salts thereof.

[0090] Thus, in one embodiment, the insulin modulator is selected from exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide, dulaglutide (LY2189265), sitagliptin, vildagliptin, saxagliptin, linagliptin, alagliflozin, teneligliptin, alogliptin, trelagliptin, gemagliptin, dutogliptin, omagliflozin (MK-3102), clofibrate, gemfibrozil, ciprofibrate, bezafibrate, fenofibrate, saxaglitazar, aleglitazar, moglitazole, tesaglitazar, insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin degludec, insulin glargine, and pharmaceutically acceptable salts thereof.

[0091] In one embodiment, the insulin modulator is a GLP-1 agonist selected from exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide, dulaglutide (LY2189265) and pharmaceutically acceptable salts thereof. The GLP-1 agonist is preferably exenatide.

[0092] Exenatide

[0093] In a preferred embodiment, the insulin modulator is selected from exenatide and its structural and functional analogs and pharmaceutically acceptable salts thereof.

[0094] In a preferred embodiment, Exenatide is in the form of a pharmaceutically acceptable salt, more preferably in the form of Exenatide acetate. In another preferred embodiment, Exenatide is in the form of a free base.

[0095] As used herein, the term "exenatide" refers to a 39 amino acid peptide having the following sequence:

[0096] H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

[0097] Exenatide (synonymous with exendin 4) was originally isolated from the saliva of the Gila monster (Heloderma suspectum) by Eng in 1992. It is an insulin secretagogue with glucose-regulating effects similar to human glucagon-like peptide-1 (GLP-1).

[0098] Exenatide mimics human glucagon-like peptide 1 (GLP-1), an intestinal incretin hormone released in response to nutrient intake (Goke et al., J. Biol. Chem., 1993, 268: 19650-19655). It exerts insulinotropic and insulinotropic properties through the GLP-1 receptor. The GLP-1 receptor is widely expressed in many organs, including the heart and vascular endothelium (Bullock et al., Endocrinology, 1996, 137: 2968-2978; Nystrom et al., Am J Physiol Endocrinol Metab, 2004, 287: E1209-E1215). Currently, Exenatide has been approved as an antidiabetic drug for the treatment of patients with type 2 diabetes. The recommended dose for this indication is an initial dose of 5 μg (μg) twice a day, which is increased to 10 μg twice a day after 1 month based on clinical response.

[0099] GLP-1 is ineffective as a therapeutic agent because it has a very short circulation half-life (less than 2 minutes) due to rapid degradation by dipeptidyl peptidase-4. Exenatide has 50% homology to GLP-1, but has a half-life of 2.4 hours in humans due to the absence of a dipeptidyl peptidase-4 cleavage site.

[0100] Exenatide enhances glucose-dependent insulin secretion by pancreatic β-cells, thereby inhibiting inappropriately elevated glucagon secretion and slowing gastric emptying. Exenatide is highly potent, with a minimum effective concentration of 50 pg / mL (12 pM) in humans. Current treatment with exenatide involves twice-daily injections In addition, sustained-release preparations It is approved for once-weekly injection.

[0101] As used herein, a functional analog of exenatide refers to a compound having a similar structure but different from it in some aspects (for example, the functional analog may differ in one or more atoms, functional groups, amino acid residues or substructures, which are replaced by other parts). Functional analogs exhibit similar pharmacological properties and may be structurally related.

[0102] In one embodiment, the structural or functional analog of exenatide is a structural or functional analog of exenatide modified to extend the half-life, such as a conjugate of exenatide.

[0103] In a preferred embodiment, the structural or functional analog of exenatide is PEGylated exenatide. For example, in a preferred embodiment, the structural or functional analog is a monoPEGylated exenatide with a PEG of 40 kDa. PEGylated exenatide can be prepared by known methods in the art. For example, PEGylated forms of exenatide are described in WO2013 / 059323 (Prolynx LLC), the contents of which are incorporated herein by reference. Exenatide can also be conjugated to other molecules, such as proteins.

[0104] In a particularly preferred embodiment, the structural or functional analog of exenatide is in a sustained release form, for example, sold under the trade name In another preferred embodiment, the structural or functional analog of Exenatide is in the form of multilayer nanoparticles for sustained delivery, for example, as described in Kim JY et al., Biomaterials, 2013; 34: 8444-9, the contents of which are incorporated herein by reference.

[0105] In another particularly preferred embodiment, Exenatide is in injectable form, such as that sold under the trade name Sold in injectable form.

[0106] Functional analogs of exenatide include GLP receptor agonists. Suitable functional analogs of exenatide include lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265).

[0107] In one embodiment, functional analogs of Exenatide include modified Exenatide, wherein one or more amino acid residues are replaced by another amino acid residue and / or wherein one or more amino acid residues are deleted and / or wherein one or more amino acid residues are added and / or inserted.

[0108] In one embodiment, the functional exenatide analog comprises less than 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, or comprises less than 9, 8, 7, 6, 5, 4, 3 or 2 modifications relative to exenatide.

[0109] In one embodiment, the functional exenatide analog comprises 10 amino acid modifications (substitutions, deletions, additions (including insertions) and any combination thereof) relative to exenatide, or comprises 9, 8, 7, 6, 5, 4, 3 or 2 modifications relative to exenatide.

[0110] As used herein, structural or functional analogs of Exenatide also include salts, isomers, enantiomers, solvates, polymorphs, prodrugs and metabolites thereof.

[0111] Aldosterone antagonists

[0112] In one embodiment, the combination of the invention comprises, in addition to the above-mentioned sulfonylurea component, an aldosterone antagonist.

[0113] Acute myocardial infarction and its subsequent hemodynamic changes lead to complex neurohormonal activation. The renin-angiotensin-aldosterone pathway is the basis of this neurohormonal activation. It is reported that aldosterone, which is present at the highest level after acute myocardial infarction, promotes a wide spectrum of adverse cardiovascular effects, including acute endothelial dysfunction, inhibition of NO activity, increased endothelial oxidative stress, increased vascular tone, inhibition of tissue reacquisition of catecholamines, rapid onset of vascular smooth muscle cell and cardiomyocyte necrosis, collagen deposition in blood vessels, myocardial hypertrophy and fibrosis (Struthers, Am Heart J, 2002, 144: S2-S7; Zannad and Radauceanu, Heart Fail Rev, 2005, 10: 71-78). In addition, it has been found to be predictive of adverse outcomes (Beygui et al., Circulation, 2006, 114: 2604-2610).

[0114] Aldosterone antagonists or antimineralocorticoids are diuretics that antagonize the effects of aldosterone on the mineralocorticoid receptors. This group of drugs is often used to treat chronic heart failure. Such members are also used to treat hyperaldosteronism (including Conn syndrome) and hirsutism in women (due to additional anti-androgenic effects). Most antimineralocorticoids are the steroid spironolactone.

[0115] Antagonism of the mineralocorticoid receptor inhibits the reabsorption of sodium in the collecting ducts of the nephrons in the kidneys. This interferes with the sodium / potassium exchange, thereby reducing urinary potassium excretion and slightly increasing water excretion (diuresis). In congestive heart failure, aldosterone antagonists are used, among other drugs, for an additional diuretic effect, thereby reducing edema and cardiac load.

[0116] Based on the results of the EPHESUS trial, current guidelines recommend the use of mineralocorticoid receptor antagonists in patients with heart failure after myocardial infarction.

[0117] Several studies in animal models and clinics of acute myocardial infarction have shown the benefits of aldosterone blockade in preventing reperfusion injury and improving cardiac function in patients with STEMI. There are indications in the literature that mineralocorticoid receptor antagonists may have beneficial effects in the cerebrovascular and during stroke (Dinh QN et al., Neural Regen Res. 2016; 11: 1230-1).

[0118] Examples of aldosterone antagonists include spironolactone (the first and most widely used member of this class), eplerenone (more selective for the target than spironolactone, but less potent and effective), canrenone and canrenoate potassium, finerenone (nonsteroidal and more effective and selective than eplerenone or spironolactone), and prorenone. Some drugs have secondary antimineralocorticoid effects in addition to their primary mechanism of action. Examples include progesterone, drospirenone, gestodene, and benidipine.

[0119] In a particularly preferred embodiment, the aldosterone antagonist is potassium canrenoate.

[0120] The present invention also includes structural and functional analogs of aldosterone antagonists, particularly structural and functional analogs of aldosterone antagonists that have been modified so as to increase the half-life of the agent, such as conjugates of aldosterone antagonists.

[0121] Potassium canrenoate

[0122] Potassium canrenoate or canrenone potassium, also known as the potassium salt of canrenoic acid, is an aldosterone antagonist of the spironolactone group. Like spironolactone, it is a prodrug that is metabolized to canrenone in the body. Potassium canrenoate is usually given intravenously at a dose of 200 mg / day to 600 mg / day for the treatment of hyperaldosteronism or hypokalemia.

[0123] The systematic (IUPAC) name of potassium canrenoate is potassium 3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16octahydro-1H-cyclopenta[a]phenanthrene-17-yl]propanoate, and the molecular formula is C 22 H 29 KO4 and its chemical structure is as follows:

[0124]

[0125] combination

[0126] In one aspect, the invention relates to a combination comprising:

[0127] (a) sulfonylureas; and

[0128] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0129] The preferred embodiments described below apply mutatis mutandis to other aspects of the invention, including methods, uses, products and compositions.

[0130] In a preferred embodiment, the combination comprises a sulfonylurea and an insulin modulator.

[0131] In a preferred embodiment, the combination consists of a sulfonylurea and an insulin modulator.

[0132] In another preferred embodiment, the combination comprises a sulfonylurea and an aldosterone antagonist.

[0133] In another preferred embodiment, the combination consists of a sulfonylurea and an aldosterone antagonist.

[0134] In another preferred embodiment, the combination comprises a sulfonylurea, an insulin modulator and an aldosterone antagonist.

[0135] In another preferred embodiment, the combination consists of a sulfonylurea, an insulin modulator and an aldosterone antagonist.

[0136] In one embodiment, an insulin modulator is defined according to any of the above embodiments of an insulin modulator.

[0137] In one embodiment, the aldosterone antagonist is defined according to any of the above embodiments of the aldosterone antagonist.

[0138] In one embodiment, the sulfonylurea is defined according to any of the above embodiments of the sulfonylurea.

[0139] In a preferred embodiment, the present invention relates to a combination comprising:

[0140] (a) glibenclamide or a structural or functional analogue thereof; and

[0141] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof. Preferably, the combination comprises (b)(i) and (b)(ii).

[0142] In a preferred embodiment, the present invention relates to a combination comprising:

[0143] (a) at least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliclazide, gliclazide, glipartide, gliclazide, chlorpropamide, tolbutamide, acetohexamide, amoxicillin, glycyrrhizide, tolbutamide, methacramide and tolazamide; and

[0144] (b) at least one of the following components:

[0145] (i) at least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof, and

[0146] (ii) at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or a pharmaceutically acceptable salt thereof (e.g. a pharmaceutically acceptable salt of canrenone, spironolactone, eplerenone, finerenone and pyrenone), as appropriate.

[0147] In one embodiment, the invention relates to a combination comprising:

[0148] At least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amosulfuronamide, glyclocyclamide, tolbutamide, metabolamide, and tolazamide; and

[0149] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof, and

[0150] At least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or pharmaceutically acceptable salts thereof, as appropriate.

[0151] In one embodiment, the invention relates to a combination comprising:

[0152] At least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amosulfuronamide, glyclocyclamide, tolbutamide, metabolamide, and tolazamide; and

[0153] At least one of exenatide, lixisenatide, albiglutide, liraglutide, taseroglutide and dulaglutide (LY2189265) or pharmaceutically acceptable salts thereof.

[0154] In another embodiment, the invention relates to a combination comprising:

[0155] At least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amosulfuronamide, glyclocyclamide, tolbutamide, metabolamide, and tolazamide; and

[0156] At least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or pharmaceutically acceptable salts thereof, as appropriate.

[0157] In one embodiment, the present invention relates to a combination or a combination comprising:

[0158] Exenatide or a pharmaceutically acceptable salt thereof, and

[0159] At least one of glibenclamide, glibourea, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amobutamide, glyclocyclamide, tolbutamide, metabolamide and tolazamide.

[0160] In one embodiment, the present invention relates to a combination or a combination comprising:

[0161] Exenatide or a pharmaceutically acceptable salt thereof, and

[0162] At least one of glibenclamide, gliprexa, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide.

[0163] In one embodiment, the present invention relates to a combination or a combination comprising:

[0164] Exenatide or a pharmaceutically acceptable salt thereof, and

[0165] Glyburide.

[0166] In one embodiment, the present invention relates to a combination or a combination comprising:

[0167] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof, and

[0168] Glyburide.

[0169] In one embodiment, the present invention relates to a combination or a combination comprising:

[0170] Potassium canrenoate, and

[0171] At least one of glibenclamide, glibourea, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amobutamide, glyclocyclamide, tolbutamide, metabolamide and tolazamide.

[0172] In one embodiment, the present invention relates to a combination or a combination comprising:

[0173] Potassium canrenoate, and

[0174] At least one of glibenclamide, gliprexa, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide.

[0175] In one embodiment, the present invention relates to a combination or a combination comprising:

[0176] at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or a pharmaceutically acceptable salt thereof, as appropriate, and

[0177] Glyburide.

[0178] In one embodiment, the present invention relates to a combination or a combination comprising:

[0179] Potassium canrenoate; and

[0180] Glyburide.

[0181] In one embodiment, the invention relates to a combination comprising:

[0182] Glyburide; and

[0183] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof, and

[0184] At least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or pharmaceutically acceptable salts thereof, as appropriate.

[0185] In one embodiment, the invention relates to a combination comprising:

[0186] At least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amosulfuronamide, glyclocyclamide, tolbutamide, metabolamide, and tolazamide; and

[0187] Exenatide or a pharmaceutically acceptable salt thereof, and

[0188] At least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or pharmaceutically acceptable salts thereof, as appropriate.

[0189] In one embodiment, the invention relates to a combination comprising:

[0190] At least one of glibenclamide, glipotamide, gliclazide, glipizide, glimepiride, gliquidone, glisapride, glyclopyramide, chlorpropamide, tolbutamide, acetohexamide, amosulfuronamide, glyclocyclamide, tolbutamide, metabolamide, and tolazamide; and

[0191] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiroglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof, and

[0192] Potassium canrenoate or canrenone.

[0193] In one embodiment, the present invention relates to a combination or a combination comprising:

[0194] Exenatide or its pharmaceutically acceptable salt

[0195] Potassium canrenoate; and

[0196] Glyburide.

[0197] In one aspect of the invention, for each of the above embodiments, the combination consists of a sulfonylurea and an aldosterone antagonist and / or an insulin regulator, i.e. they are the only active agents. In another (optional) aspect, the combination further comprises one or more additional active agents as described below.

[0198] The effects of drug combinations are inherently unpredictable, and there is often a tendency for one drug to partially or completely inhibit the effects of another drug. The present invention demonstrates that when a combination comprising the following substances is administered simultaneously, separately or sequentially, no significant or significant adverse interactions between the two agents will result: a sulfonylurea such as glibenclamide or a structural or functional analog thereof, and (i) an insulin regulator such as exenatide or a structural or functional analog thereof or a pharmaceutically acceptable salt thereof and (ii) at least one of an aldosterone antagonist such as potassium canrenoate or a structural or functional analog thereof. The unexpected absence of any such antagonistic interactions is crucial for the clinical application of the combination.

[0199] Furthermore, the preferred combinations according to the invention surprisingly show a potentiation of the effects of the individual components, such that the optimal doses of the agents are lower than the recommended doses of these agents in approved indications and / or also lower than the doses reported in the literature for reperfusion injury.

[0200] In one embodiment, the combination of active agents of the invention produces an enhanced effect compared to each agent administered alone.

[0201] As an illustration, the applicant's studies have shown that the preferred dose of glibenclamide that produces a synergistic effect in the case of the combination claimed in the present invention is significantly lower than the dose previously reported in the literature for lowering blood sugar (e.g., diabetes). In fact, the preferred dose of glibenclamide used in the combination claimed in the present invention is about ~20 to 285 times lower than the recommended maintenance dose of glibenclamide (micronized formulation) for the treatment of diabetes (for micronized formulation of glibenclamide, the recommended maintenance daily dose is 1.25 mg to 20 mg, for a 70 kg adult, this corresponds to 18 μ8 kg to 285 μ85 kg, which is quite different from the preferred dose of glibenclamide required in the combination therapy claimed in the present invention, which can be as low as 1 μg / kg body weight). Advantageously, the use of glibenclamide at these preferred lower doses avoids any effect on blood sugar levels, which could otherwise lead to adverse side effects. The applicant's research also shows that the clinically effective dose of glibenclamide used as a dual or triple combination according to the present invention together with a low dose of exenatide and / or potassium canrenoate is also significantly lower than the dose of glibenclamide that showed neuroprotection in clinical studies disclosed in the literature (continuous infusion of 0.16 mg / h or 0.11 mg / h, i.e. 3.84 mg or 2.64 mg per day) (see King ZA et al.).

[0202] Furthermore, in another embodiment, the combination of active agents of the present invention produces an unexpected synergistic effect, for example, in the treatment and / or prevention of reperfusion injury, in particular cerebral or myocardial reperfusion injury.

[0203] Combinations of two or more drugs may result in different types of drug interactions. A drug interaction is considered additive when the combined effect of the two drugs is equal to the sum of the effects of each agent given alone. A drug interaction is considered synergistic if the combined effect of the two drugs exceeds the total effect of each agent given alone (Goodman and Gilmans, "The Pharmacological Basis of Therapeutics," 12th edition).

[0204] Combination therapy is an important treatment modality for many disease conditions, including cardiovascular disease, cancer, and infectious diseases. Recent scientific advances have deepened the understanding of the pathophysiological processes behind these and other complex diseases. This enhanced understanding provides further impetus for the development of new treatment methods that use combinations of drugs directed to multiple therapeutic targets to improve treatment response, minimize the development of resistance, or minimize adverse events. In situations where combination therapy offers significant therapeutic advantages, there is increasing interest in the development of new combinations of two or more drugs.

[0205] Advantageously, a synergistic combination may allow each component to be present in a lower dosage, thereby reducing the toxicity of the treatment while producing and / or maintaining the same therapeutic effect or an enhanced therapeutic effect. Thus, in particularly preferred embodiments, each component of the combination is present in a subtherapeutic amount. The term "subtherapeutically effective amount" refers to an amount that is lower than the amount normally required to produce a therapeutic effect for treatment using each agent alone.

[0206] In one embodiment, the present invention relates to a synergistic combination comprising a sulfonylurea and an insulin modulator.

[0207] In another embodiment, the present invention relates to a synergistic combination comprising a sulfonylurea and an aldosterone antagonist.

[0208] In another embodiment, the present invention is directed to a synergistic combination comprising a sulfonylurea, an insulin modulator, and an aldosterone antagonist.

[0209] In one embodiment, an insulin modulator is defined according to any of the above embodiments of an insulin modulator.

[0210] In one embodiment, the aldosterone antagonist is defined according to any of the above embodiments of the aldosterone antagonist.

[0211] In one embodiment, the sulfonylurea is defined according to any of the above embodiments of the sulfonylurea.

[0212] In one embodiment, the present invention relates to a synergistic combination comprising a sulfonylurea and at least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof.

[0213] In one embodiment, the present invention relates to a synergistic combination comprising a sulfonylurea and, as the case may be, at least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or a pharmaceutically acceptable salt thereof.

[0214] In one embodiment, the invention relates to a synergistic combination comprising:

[0215] At least one of glibenclamide, glipoteur, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide; and

[0216] at least one of exenatide or a pharmaceutically acceptable salt thereof, and

[0217] Potassium canrenoate.

[0218] In one embodiment, the invention relates to a synergistic combination comprising:

[0219] at least one of glibenclamide, glipoteur, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide;

[0220] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof; and

[0221] Potassium canrenoate.

[0222] In one embodiment, the invention relates to a synergistic combination comprising:

[0223] At least one of exenatide, lixisenatide, albiglutide, liraglutide, tasiglutide and dulaglutide (LY2189265) or a pharmaceutically acceptable salt thereof; and

[0224] Glyburide.

[0225] In one embodiment, the invention relates to a synergistic combination comprising:

[0226] Exenatide or a pharmaceutically acceptable salt thereof; and

[0227] Glyburide.

[0228] In one embodiment, the invention relates to a synergistic combination comprising:

[0229] Exenatide or a pharmaceutically acceptable salt thereof; and

[0230] At least one of glibenclamide, gliprexa, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide.

[0231] In one embodiment, the invention relates to a synergistic combination comprising:

[0232] At least one of potassium canrenoate, canrenone, spironolactone, eplerenone, finerenone and pyrenone or a pharmaceutically acceptable salt thereof; and

[0233] Glyburide.

[0234] In one embodiment, the invention relates to a synergistic combination comprising:

[0235] Potassium canrenoate; and

[0236] At least one of glibenclamide, gliprexa, gliclazide, glipizide, glimepiride, gliquidone, glisapride and glypyruvide.

[0237] In one embodiment, the present invention relates to a synergistic combination comprising potassium canrenoate and glibenclamide.

[0238] In one embodiment, the present invention relates to a synergistic combination comprising exenatide or a pharmaceutically acceptable salt thereof, potassium canrenoate and glibenclamide.

[0239] Other active pharmaceutical ingredients

[0240] In one embodiment, the above combination comprises at least one additional active pharmaceutical ingredient (API).

[0241] In one embodiment, the above combination may further comprise at least one other API selected from the group consisting of beta blockers, renin-angiotensin inhibitors, statins (HMG-CoA reductase inhibitors), platelet activation or aggregation inhibitors, phosphodiesterase-3 inhibitors, calcium sensitizers, antioxidants and anti-inflammatory agents.

[0242] Examples of beta-blockers include propranolol, metoprolol, bucinolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, and timolol.

[0243] Renin-angiotensin inhibitors include angiotensin converting enzyme inhibitors, angiotensin AT1 receptor inhibitors and renin inhibitors.

[0244] Examples of angiotensin converting enzyme inhibitors include captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, and fosinopril.

[0245] Examples of angiotensin AT1 receptor antagonists include losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan, and telmisartan.

[0246] Examples of renin inhibitors include remiskiren and aliskiren.

[0247] Examples of calcium sensitizers include levosimendan and its analogs.

[0248] Examples of statins include atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin.

[0249] Examples of platelet activation or aggregation inhibitors include prostacyclins (epoprostenol) and their structural and functional analogs (e.g., treprostinil, iloprost), irreversible cyclooxygenase inhibitors (e.g., aspirin, triflusal), adenosine diphosphate (ADP) receptor inhibitors (e.g., clopidogrel, prasugrel, ticagrelor, ticlopidine), phosphodiesterase inhibitors (e.g., cilostazol), protease activated receptor-1 (PAR-1) antagonists (e.g., vorapaxar), glycoprotein IIB / IIIA inhibitors (e.g., abciximab, eptifibatide, tirofiban), adenosine reuptake inhibitors (e.g., dipyridamole), and thromboxane inhibitors, including thromboxane synthetase inhibitors and thromboxane receptor antagonists (e.g., trutroban).

[0250] Examples of phosphodiesterase-3 (PDE-3) inhibitors include amrinone, milrinone, and analogs thereof.

[0251] Examples of antioxidants include ascorbic acid, lipoic acid, glutathione, melatonin, and resveratrol.

[0252] Examples of anti-inflammatory agents include COX-2 inhibitors (eg, celecoxib), glucocorticoids (eg, hydrocortisone), and nonsteroidal anti-inflammatory drugs (eg, ibuprofen).

[0253] In one embodiment, the above combination comprises at least one additional API selected from the group consisting of propranolol, metoprolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan, telmisartan, remikiren, aliskiren, melatonin and resveratrol.

[0254] In another embodiment, the above combination comprises at least one additional API selected from the group consisting of carvedilol, metoprolol, losartan, irbesartan, olmesartan, candesartan, valsartan, fimasartan, telmisartan, captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril, fosinopril, remikiren, aliskiren, melatonin and resveratrol.

[0255] In another embodiment, the above combination comprises at least one additional API selected from carvedilol, metoprolol, melatonin and resveratrol.

[0256] Pharmaceutically acceptable salts

[0257] The active pharmaceutical ingredients of the present invention may be present in the form of pharmaceutically acceptable salts.

[0258] Pharmaceutically acceptable salts of the agents of the present invention include suitable acid addition salts or base salts thereof. For a review of suitable pharmaceutically acceptable salts, reference may be made to Berge et al., J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or hydrohalic acids (e.g. HCl, HBr); strong organic carboxylic acids, such as unsubstituted or substituted (e.g. substituted by halogen) alkanecarboxylic acids having 1 to 4 carbon atoms, such as acetic acid; saturated or unsaturated dicarboxylic acids, for example oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or tetraphthalic acid; hydroxycarboxylic acids, such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; amino acids, such as aspartic acid or glutamic acid; benzoic acid; or organic sulfonic acids, such as unsubstituted or substituted (e.g. substituted by halogen) (C1-C4)-alkylsulfonic acids or arylsulfonic acids, such as methanesulfonic acid or p-toluenesulfonic acid.

[0259] Enantiomers / Tautomers

[0260] The present invention also suitably includes all enantiomers and tautomers of active pharmaceutical preparations. Those skilled in the art will recognize compounds with optical properties (one or more chiral carbon atoms) or tautomeric characteristics. The corresponding enantiomers and / or tautomers can be separated / prepared by methods known in the art.

[0261] Stereo and geometric isomers

[0262] Some active pharmaceutical preparations of the present invention may exist in stereoisomer and / or geometric isomer forms, which may have one or more asymmetric centers and / or geometric centers, and thus may exist in two or more stereoisomer and / or geometric isomer forms. The present invention encompasses the use of all individual stereoisomers and geometric isomers of those inhibitors, as well as mixtures thereof. The terms used in the claims include these forms, provided that the form retains the appropriate functional activity (although not necessarily to the same extent).

[0263] The present invention also includes all suitable isotopic variations of the active pharmaceutical agent or a pharmaceutically acceptable salt thereof. An isotopic variation of the agent of the present invention or a pharmaceutically acceptable salt thereof is defined as the case where at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be introduced into the agent and its pharmaceutically acceptable salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, for example, 2 H. 3 H. 13 C. 14 C.15 N. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F and 36 Certain isotopic variations of the agent and its pharmaceutically acceptable salts are useful in drug and / or substrate tissue distribution studies, such as those incorporating radioactive isotopes (e.g. 3 H or 14 C) isotopic variant. For ease of preparation and detection, tritium (i.e. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred. In addition, the use of isotopes (e.g. deuterium, i.e. 2 H) may provide a certain degree of therapeutic advantage due to its greater metabolic stability, such as an extension of half-life in vivo or a reduction in dosage requirements, and therefore it may be preferred in certain circumstances. In general, isotopic variations of the present invention's agents and pharmaceutically acceptable salts thereof can be prepared by conventional methods using appropriate isotopic variations of suitable agents.

[0264] Solvate

[0265] The present invention also includes solvated forms of the active pharmaceutical preparations of the present invention. The terms used in the claims include these forms.

[0266] Polymorph

[0267] The present invention also relates to the active pharmaceutical preparations of the present invention in their various crystalline forms, polymorphic forms and anhydrous / hydrated forms. Such methods are well established in the pharmaceutical art: compounds in any of the described forms can be isolated by slightly changing the purification methods and / or isolation forms of the solvents used to synthesize the compounds.

[0268] Pharmaceutical composition

[0269] In another aspect, the present invention relates to a pharmaceutical composition comprising a combination according to the present invention as described above and a pharmaceutically acceptable carrier, diluent or excipient.

[0270] In one aspect, the present invention relates to a pharmaceutical composition comprising:

[0271] (a) sulfonylureas; and

[0272] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0273] and a pharmaceutically acceptable carrier, diluent or excipient.

[0274] In a preferred embodiment, the present invention relates to a pharmaceutical composition comprising:

[0275] (a) glibenclamide or a structural or functional analog thereof; and a pharmaceutically acceptable carrier, diluent or excipient; and

[0276] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof;

[0277] and a pharmaceutically acceptable carrier, diluent or excipient.

[0278] In one aspect, the present invention relates to a pharmaceutical composition consisting of the following substances:

[0279] (a) sulfonylureas; and

[0280] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0281] and a pharmaceutically acceptable carrier, diluent or excipient.

[0282] In a preferred embodiment, the present invention relates to a pharmaceutical composition consisting of the following substances:

[0283] (a) glibenclamide or a structural or functional analog thereof; and a pharmaceutically acceptable carrier, diluent or excipient; and

[0284] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof;

[0285] and a pharmaceutically acceptable carrier, diluent or excipient.

[0286] Although the compounds of the invention (including their pharmaceutically acceptable salts) can be administered alone, they are usually administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy. The pharmaceutical compositions can be used for human or non-human animal applications in human medicine or veterinary medicine, respectively.

[0287] Examples of such suitable excipients for use in the various forms of the pharmaceutical compositions described herein can be found in "Handbook of Pharmaceutical Excipients," 2nd edition, edited by A Wade and PJ Weller (1994).

[0288] Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro, ed., 1985).

[0289] The selection of pharmaceutical carrier, excipient or diluent can be selected according to the expected route of administration and standard pharmaceutical practice. Examples of routes of administration include parenteral (e.g., intravenous, intramuscular, intradermal, intraperitoneal or subcutaneous), oral, inhalation, transdermal (topical), intraocular, iontophoresis and transmucosal administration.

[0290] In one embodiment, the pharmaceutical composition is for parenteral administration (eg, intravenous, intraarterial, intrathecal, intramuscular, intradermal, intraperitoneal, or subcutaneous).Preferably, the composition is prepared from a sterile or sterilizable solution.

[0291] In another embodiment, the pharmaceutical composition is for intravenous, intramuscular or subcutaneous administration.

[0292] In another embodiment, the pharmaceutical composition is for intravenous administration.

[0293] Solutions or suspensions for parenteral, intradermal or subcutaneous administration may contain the following components: a sterile diluent, such as water for injection, saline solution, fixed oils, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and osmotic pressure regulators, such as sodium chloride or glucose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.

[0294] Pharmaceutical compositions suitable for injectable use may include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor TM Or phosphate buffered saline (PBS). In all cases, the composition for parenteral administration must be sterile and should be fluid to the extent that it is easy to inject. It should be stable under the conditions of manufacture and storage, and must be preserved to resist the contaminating effects of microorganisms (such as bacteria and fungi).

[0295] Sterile injectable solutions can be prepared in such a way that the required amount of active compound is incorporated into a suitable solvent with one or a combination of ingredients listed above as required, and then filtered and sterilized. Typically, dispersions are prepared by incorporating the active compound into a sterile carrier containing a basic dispersion medium and other ingredients required from the above-listed components. In the case of sterile powders for the preparation of sterile injectable solutions, typical preparation methods include vacuum drying and freeze drying, which can produce powders of the active ingredient plus any other desired ingredients from their previously sterile filtered solutions. The present invention also encompasses liposomes and nanoparticle formulations containing active agents. These preparations and their preparation methods are familiar to those of ordinary skill in the art.

[0296] Pharmaceutical products

[0297] In another aspect, the present invention relates to a pharmaceutical product comprising:

[0298] (a) sulfonylureas; and

[0299] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0300] In a preferred embodiment, the present invention relates to a pharmaceutical product comprising:

[0301] (a) glibenclamide or a structural or functional analogue thereof; and

[0302] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0303] In another aspect, the present invention relates to a pharmaceutical product consisting of:

[0304] (a) sulfonylureas; and

[0305] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0306] In a preferred embodiment, the present invention relates to a pharmaceutical product consisting of:

[0307] (a) glibenclamide or a structural or functional analogue thereof; and

[0308] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0309] In a preferred embodiment, each component of the pharmaceutical product is for separate administration.

[0310] In one embodiment, the drug product is a kit of parts containing all necessary equipment for a treatment procedure (eg, drug vial, diluent vial, syringe, and needle).

[0311] The components of the kit and pharmaceutical product are as defined above. In a preferred embodiment, each component of the kit or pharmaceutical product is admixed with one or more pharmaceutically acceptable diluents, excipients and / or carriers.

[0312] In one embodiment, the kit includes separate containers for each active agent. The container may be an ampoule, a disposable syringe or a multiple dose vial.

[0313] In another embodiment, the kit includes a container containing the combined preparation of the individual active agents.

[0314] The kit may further include instructions for treating and / or preventing reperfusion injury.

[0315] Medical Uses

[0316] The present invention also relates to the use of the above-mentioned combination, pharmaceutical product or pharmaceutical composition in the treatment of various therapeutic conditions as described in detail below, as well as the treatment methods related thereto.

[0317] In a preferred embodiment, each pharmaceutically active ingredient of the combination, pharmaceutical product or pharmaceutical composition is administered separately.

[0318] In one aspect, the present invention relates to the following use of a combination: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection, for example, against neurotoxic drugs; the combination comprises:

[0319] (a) sulfonylureas; and

[0320] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0321] In a preferred embodiment, the combination is used to provide neuroprotection. Preferably, the combination is used to provide neuroprotection against neurotoxic drugs.

[0322] In a preferred embodiment, the present invention relates to the following uses of a combination: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative diseases, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs; the combination comprises:

[0323] (a) glibenclamide or a structural or functional analogue thereof; and

[0324] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0325] In another aspect, the present invention relates to the following uses of a pharmaceutical composition comprising a combination: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs; the combination comprises:

[0326] (a) sulfonylureas; and

[0327] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0328] In a preferred embodiment, the present invention relates to the following uses of a pharmaceutical composition comprising a combination: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs; the combination comprises:

[0329] (a) glibenclamide or a structural or functional analogue thereof; and

[0330] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0331] In another aspect, the present invention relates to the following use of a pharmaceutical product: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs; the pharmaceutical product comprises:

[0332] (a) sulfonylureas; and

[0333] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0334] The components are used for simultaneous, sequential or separate administration.

[0335] In a preferred embodiment, the present invention relates to the following uses of a pharmaceutical product: for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative diseases, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs; the pharmaceutical product comprises:

[0336] (a) glibenclamide or a structural or functional analogue thereof; and

[0337] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof;

[0338] The components are used for simultaneous, sequential or separate administration.

[0339] In another aspect, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative disease, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs:

[0340] (a) sulfonylureas; and

[0341] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0342] In another preferred embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing one or more of ischemia and / or reperfusion injury, stroke, neurodegenerative diseases, neonatal asphyxia, cardiac arrest, cardiogenic shock and acute myocardial infarction, or for providing cardioprotection against cardiotoxic drugs, or for providing neuroprotection against neurotoxic drugs:

[0343] (a) glibenclamide or a structural or functional analogue thereof; and

[0344] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0345] In one embodiment, the present invention relates to the use of a combination for the treatment and / or prevention of reperfusion injury, the combination comprising:

[0346] (a) sulfonylureas; and

[0347] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0348] In a preferred embodiment, the present invention relates to a combination for use in treating and / or preventing reperfusion injury, the combination comprising:

[0349] (a) glibenclamide or a structural or functional analogue thereof; and

[0350] (b) at least two of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0351] In another embodiment, the present invention relates to a use of a pharmaceutical composition for treating and / or preventing reperfusion injury, the pharmaceutical composition comprising:

[0352] (a) sulfonylureas; and

[0353] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0354] In another preferred embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for treating and / or preventing reperfusion injury, the combination comprising:

[0355] (a) glibenclamide or a structural or functional analogue thereof; and

[0356] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0357] In another embodiment, the present invention relates to a use of a pharmaceutical product in the treatment and / or prevention of reperfusion injury, wherein the pharmaceutical product comprises:

[0358] (a) sulfonylureas; and

[0359] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0360] The components are used for simultaneous, sequential or separate administration.

[0361] In another preferred embodiment, the present invention relates to use of a pharmaceutical product in treating and / or preventing reperfusion injury, the pharmaceutical product comprising:

[0362] (a) glibenclamide or a structural or functional analogue thereof; and

[0363] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof;

[0364] The components are used for simultaneous, sequential or separate administration.

[0365] In another embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing reperfusion injury:

[0366] (a) sulfonylureas; and

[0367] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0368] In another preferred embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing reperfusion injury:

[0369] (a) glibenclamide or a structural or functional analogue thereof,

[0370] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0371] In a preferred embodiment, the present invention relates to the use of a combination for the treatment and / or prevention of ischemia, said combination comprising:

[0372] (a) sulfonylureas; and

[0373] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0374] In a preferred embodiment, the present invention relates to a combination for use in the treatment and / or prevention of ischemia, said combination comprising:

[0375] (a) glibenclamide or a structural or functional analogue thereof; and

[0376] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0377] In another embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for the treatment and / or prevention of ischemia, said combination comprising:

[0378] (a) sulfonylureas; and

[0379] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0380] In another preferred embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for the treatment and / or prevention of ischemia, the combination comprising:

[0381] (a) glibenclamide or a structural or functional analogue thereof; and

[0382] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0383] In another embodiment, the present invention relates to the use of a pharmaceutical product for the treatment and / or prevention of ischemia, said pharmaceutical product comprising:

[0384] (a) sulfonylureas; and

[0385] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0386] The components are used for simultaneous, sequential or separate administration.

[0387] In another preferred embodiment, the present invention relates to the use of a pharmaceutical product for the treatment and / or prevention of ischemia, the pharmaceutical product comprising:

[0388] (a) glibenclamide or a structural or functional analogue thereof; and

[0389] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof;

[0390] The components are used for simultaneous, sequential or separate administration.

[0391] In another embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing ischemia:

[0392] (a) sulfonylureas; and

[0393] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0394] In another preferred embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing ischemia:

[0395] (a) glibenclamide or a structural or functional analogue thereof; and

[0396] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0397] In a preferred embodiment, the present invention relates to the use of a combination for the treatment and / or prevention of stroke, said combination comprising:

[0398] (a) sulfonylureas; and

[0399] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0400] In a preferred embodiment, the present invention relates to the use of a combination for the treatment and / or prevention of stroke, said combination comprising:

[0401] (a) glibenclamide or a structural or functional analogue thereof; and

[0402] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0403] In another embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for the treatment and / or prevention of stroke, the combination comprising:

[0404] (a) sulfonylureas; and

[0405] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0406] In another preferred embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for treating and / or preventing stroke, the combination comprising:

[0407] (a) glibenclamide or a structural or functional analogue thereof; and

[0408] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0409] In another embodiment, the present invention relates to the use of a pharmaceutical product for the treatment and / or prevention of stroke, the pharmaceutical product comprising:

[0410] (a) sulfonylureas; and

[0411] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0412] The components are used for simultaneous, sequential or separate administration.

[0413] In another preferred embodiment, the present invention relates to the use of a pharmaceutical product in the treatment and / or prevention of stroke, the pharmaceutical product comprising:

[0414] (a) glibenclamide or a structural or functional analogue thereof; and

[0415] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof;

[0416] The components are used for simultaneous, sequential or separate administration.

[0417] In another embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for the treatment and / or prevention of stroke:

[0418] (a) sulfonylureas; and

[0419] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0420] In another preferred embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for treating and / or preventing stroke:

[0421] (a) glibenclamide or a structural or functional analogue thereof; and

[0422] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0423] In a preferred embodiment, the stroke is a hemorrhagic stroke.

[0424] In another preferred embodiment, the stroke is an ischemic stroke.

[0425] As used herein, the term "reperfusion injury" refers to tissue damage caused when blood supply returns to tissues after an ischemic period. Lack of oxygen and nutrients in the blood can cause a situation in which the restoration of circulation leads to inflammation, mitochondrial dysfunction and oxidative damage, rather than restoration of normal function, by inducing oxidative stress. Reperfusion injury can occur after spontaneous events (e.g., arterial occlusion) or planned events (e.g., any of multiple surgical treatments). Myocardial reperfusion injury can occur, for example, after myocardial infarction, or as a result of a heart transplant. Cerebral reperfusion injury can occur, for example, after ischemic stroke or as a result of neonatal asphyxia.

[0426] In one embodiment, the ischemia and / or reperfusion injury is ischemia and / or reperfusion injury to the brain, heart, lung, kidney, or other organ / tissue susceptible to ischemia and / or reperfusion injury.

[0427] In one embodiment, the ischemia and / or reperfusion injury is ischemia and / or reperfusion injury of the brain, preferably cerebral ischemia and / or cerebral reperfusion injury.

[0428] In one embodiment, the ischemia and / or reperfusion injury is cardiac ischemia and / or reperfusion injury, preferably myocardial ischemia and / or myocardial reperfusion injury.

[0429] In one embodiment, the invention relates to the use of a combination for the treatment and / or prevention of a neurodegenerative disorder, said combination comprising:

[0430] (a) sulfonylureas; and

[0431] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0432] In a preferred embodiment, the present invention relates to the use of a combination for the treatment and / or prevention of neurodegenerative disorders, said combination comprising:

[0433] (a) glibenclamide or a structural or functional analogue thereof; and

[0434] (b) at least two of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0435] In another embodiment, the present invention relates to the use of a pharmaceutical composition for treating and / or preventing a neurodegenerative disorder, the pharmaceutical composition comprising:

[0436] (a) sulfonylureas; and

[0437] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0438] In another preferred embodiment, the present invention relates to the use of a pharmaceutical composition comprising a combination for the treatment and / or prevention of neurodegenerative disorders, the combination comprising:

[0439] (a) glibenclamide or a structural or functional analogue thereof; and

[0440] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0441] In another embodiment, the present invention relates to the use of a pharmaceutical product for the treatment and / or prevention of a neurodegenerative disorder, the pharmaceutical product comprising:

[0442] (a) sulfonylureas; and

[0443] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist;

[0444] The components are used for simultaneous, sequential or separate administration.

[0445] In another preferred embodiment, the present invention relates to the use of a pharmaceutical product for the treatment and / or prevention of neurodegenerative disorders, the pharmaceutical product comprising:

[0446] (a) glibenclamide or a structural or functional analogue thereof; and

[0447] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof;

[0448] The components are used for simultaneous, sequential or separate administration.

[0449] In another embodiment, the present invention relates to the use of:

[0450] (a) sulfonylureas; and

[0451] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0452] In another preferred embodiment, the present invention relates to the use of the following substances in the manufacture of a medicament for the treatment and / or prevention of neurodegenerative disorders:

[0453] (a) glibenclamide or a structural or functional analogue thereof; and

[0454] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate or a structural or functional analogue thereof.

[0455] In a preferred embodiment, the neurodegenerative disorder is selected from Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease and Alzheimer's disease.

[0456] In a preferred embodiment, the neurodegenerative disorder is Parkinson's disease.

[0457] In a preferred embodiment, the neurodegenerative disorder is amyotrophic lateral sclerosis (ALS).

[0458] In a preferred embodiment, the neurodegenerative disorder is vascular dementia.

[0459] In a preferred embodiment, the neurodegenerative disorder is Alzheimer's disease.

[0460] The insulin modulator, aldosterone antagonist and sulfonylurea may be administered simultaneously, sequentially or separately (as part of a dosing regimen).

[0461] Exenatide or its structural or functional analogue or its pharmaceutically acceptable salt, potassium canrenoate or its structural or functional analogue and glibenclamide or its structural or functional analogue or its pharmaceutically acceptable salt may be administered simultaneously, sequentially or separately (as part of a dosing regimen).

[0462] As used herein, "simultaneously" is used to mean that two agents are administered at the same time.

[0463] As used herein, "sequentially" is used to indicate that the active agents are not administered simultaneously, but rather one after the other. Thus, "sequentially" administration may allow administration of one agent within 5 minutes, 10 minutes, or a few hours after another agent, as long as the circulating half-life of the first administered agent allows both to be present simultaneously in therapeutically effective amounts. The time delay between administration of the components varies depending on the exact nature of the components, the interactions between them, and their respective half-lives. In contrast to "sequentially," "separately" is used herein to indicate that the interval between administration of one agent and another is significant, i.e., when the second agent is administered, a therapeutically effective amount of the first administered agent may no longer be present in the bloodstream.

[0464] In one embodiment, the components of the combination are for simultaneous administration.

[0465] Treatment

[0466] In another aspect, the present invention relates to a method for treating and / or preventing ischemia and / or reperfusion injury, the method comprising simultaneously, sequentially or separately administering to a subject:

[0467] (a) sulfonylureas; and

[0468] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0469] In another preferred embodiment, the present invention relates to a method for treating and / or preventing ischemia and / or reperfusion injury, the method comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0470] (a) glibenclamide or a structural or functional analogue thereof; and

[0471] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0472] In one embodiment, the present invention relates to a method for treating and / or preventing reperfusion injury, the method comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0473] (a) sulfonylureas; and

[0474] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0475] In a preferred embodiment, the present invention relates to a method for treating and / or preventing reperfusion injury, the method comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0476] (a) glibenclamide or a structural or functional analogue thereof; and

[0477] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0478] In another embodiment, the present invention relates to a method for treating and / or preventing ischemia, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0479] (a) sulfonylureas; and

[0480] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0481] In another embodiment, the present invention relates to a method for treating and / or preventing ischemia, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0482] (a) glibenclamide or a structural or functional analogue thereof; and

[0483] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0484] In one embodiment, the method is directed to treating and / or preventing ischemia and / or reperfusion injury to the brain, heart, lung, kidney, or other organs / tissues susceptible to ischemia and / or reperfusion injury.

[0485] In one embodiment, the method is directed to treating and / or preventing reperfusion injury to the brain, heart, lung, kidney, or other organs / tissues susceptible to reperfusion injury.

[0486] In one embodiment, the method is directed to treating and / or preventing ischemia in the brain, heart, lungs, kidneys, or other organs / tissues susceptible to ischemia.

[0487] In another embodiment, the method relates to treating and / or preventing ischemia and / or reperfusion injury to the brain, preferably cerebral ischemia and / or cerebral reperfusion injury.

[0488] In another embodiment, the method relates to treating and / or preventing reperfusion injury to the brain, preferably cerebral reperfusion injury.

[0489] In another embodiment, the method relates to treating and / or preventing ischemia and / or reperfusion injury of the heart, preferably myocardial ischemia and / or myocardial reperfusion injury.

[0490] In another embodiment, the method relates to treating and / or preventing cardiac reperfusion injury, preferably myocardial reperfusion injury.

[0491] In a particularly preferred embodiment, the method relates to the treatment and / or prevention of acute myocardial infarction.Acute myocardial infarction is one of the most common clinical indications of reperfusion injury.

[0492] In a particularly preferred embodiment, the method relates to the treatment and / or prevention of stroke.

[0493] In a preferred embodiment, the stroke is a hemorrhagic stroke.

[0494] In a particularly preferred embodiment, the method relates to the treatment and / or prevention of ischemic stroke.Ischemic stroke is one of the most common clinical indications of reperfusion injury.

[0495] In another embodiment, the method relates to the treatment and / or prevention of neonatal asphyxia.

[0496] Neonatal asphyxia (or perinatal asphyxia) is a medical condition caused by a lack of oxygen to the newborn that persists long enough during birth to cause physical damage, usually to the brain. The most common causes of neonatal asphyxia are a drop in maternal blood pressure during labor or other disturbances in blood flow to the baby's brain, for example, due to inadequate circulation or perfusion, respiratory distress, or inadequate ventilation.

[0497] Neonatal asphyxia causes hypoxic damage to most of the baby's organs (heart, lungs, liver, intestines, kidneys), but brain damage is the most worrisome and perhaps the least likely to heal quickly or completely. In more severe cases, the baby survives but has brain damage that manifests as mental disability (such as developmental delay) or intellectual disability, or physical disability (such as spasticity). Babies with severe perinatal asphyxia often have poor color (cyanosis), perfusion, responsiveness, muscle tone, and respiratory behavior. Severe asphyxia can lead to cardiac arrest and death. Neonatal asphyxia affects 2 to 10 out of every 1,000 full-term newborns, and more cases occur in premature newborns. The WHO estimates that birth asphyxia kills 4 million newborns each year, accounting for 38% of deaths in children under the age of 5.

[0498] In another embodiment, the method relates to the treatment and / or prevention of cardiac ischemia, preferably myocardial ischemia.

[0499] In another embodiment, the present invention relates to a method for treating and / or preventing stroke, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0500] (a) sulfonylureas; and

[0501] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0502] In another embodiment, the present invention relates to a method for treating and / or preventing stroke, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0503] (a) glibenclamide or a structural or functional analogue thereof; and

[0504] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0505] In another embodiment, the present invention relates to a method for treating and / or preventing a neurodegenerative disease, the method comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0506] (a) sulfonylureas; and

[0507] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0508] In another embodiment, the present invention relates to a method for treating and / or preventing a neurodegenerative disease, the method comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0509] (a) glibenclamide or a structural or functional analogue thereof; and

[0510] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0511] In another embodiment, the invention relates to a method of providing neuroprotection, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0512] (a) sulfonylureas; and

[0513] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0514] In another embodiment, the invention relates to a method of providing neuroprotection, comprising simultaneously, sequentially or separately administering to a subject in need thereof:

[0515] (a) glibenclamide or a structural or functional analogue thereof; and

[0516] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0517] In one embodiment, the subject is a mammal, more preferably a human.

[0518] In one embodiment, the method comprises administering each component to a subject parenterally (e.g., intravenously, intramuscularly, intradermally, intraperitoneally, or subcutaneously). The combined pharmaceutically active components may be administered alone or as a combined preparation. Preferably, the pharmaceutically active components are administered alone.

[0519] In another embodiment, the method comprises administering the components to the subject intravenously, intramuscularly, or subcutaneously.

[0520] In another embodiment, the method comprises administering the components intravenously to the subject.

[0521] Each component can be administered by the same or different route as the other components. Preferably, each component is administered by the same route.

[0522] In one embodiment, the combination is administered to a donor subject and / or a recipient subject before and / or during and / or after a heart transplant. For example, in some embodiments, the combination can be administered to a first subject, and a heart organ removed from the first subject is used for transplantation into a second subject. Additionally or alternatively, in some embodiments, the combination is administered to the removed heart organ before the heart organ is introduced into a second subject. Additionally or alternatively, in some embodiments, the combination therapy is administered to a second subject before, during, and / or after a heart transplant.

[0523] In one embodiment, the combination is used to administer to a subject having a stroke. A stroke is when poor blood flow to the brain causes cell death. There are two main types of stroke: ischemic stroke (due to lack of blood flow) and hemorrhagic stroke (due to bleeding). They cause part of the brain to not work properly. Signs and symptoms of a stroke may include being unable to move or feel one side of the body, problems understanding or speaking, feeling like the world is spinning, or loss of vision on one side. An ischemic stroke is usually caused by a blockage in a blood vessel. Treatment of an ischemic stroke involves surgery to open (reperfuse) an artery to the brain that has the narrowing problem. If an ischemic stroke is discovered within three to four and a half hours, it can be treated with drugs that can break up the clot. In 2013, stroke was the second most common cause of death after coronary artery disease, causing 6.4 million deaths (12% of the total).

[0524] Ischemic stroke and acute myocardial infarction require urgent reperfusion to improve functional outcomes (Patel and Saver, 2013, Stroke, 44: 94-98). For a long time, intravenous tissue plasminogen activator has been the only reperfusion therapy that has been proven to be clinically beneficial for patients with acute ischemic stroke. As occurs in acute myocardial infarction, intravascular approaches to restore reperfusion in acute ischemic stroke may subject patients to more severe ischemia / reperfusion injury, thereby hindering the benefits of recanalization by promoting both hemorrhagic transformation and severe vascular edema, which are markers of reperfusion injury (Bai and Lyden, 2015, Int J Stroke, 10: 143-152). Experimental evidence suggests that cerebral ischemia-reperfusion injury (as occurs in myocardial reperfusion injury) may be alleviated by ischemic preconditioning and postconditioning. In rats, glibenclamide showed enhanced therapeutic benefits for early hypothermia after severe stroke (Zhu S et al., Aging Dis. 2018; 9: 685-695). In addition, in a clinically relevant rat model of stroke (middle cerebral artery occlusion), reperfusion was initiated 4.5 h later, accompanied by administration of recombinant tissue plasminogen activator, followed by administration of glibenclamide (10 μg / kg IP loading dose plus 200 ng / h, by constant subcutaneous infusion) 4.5 h or 10 h after the onset of ischemia; glibenclamide significantly reduced hemispheric swelling at 24 h and mortality at 48 h, and improved the Garcia score at 48 h, indicating that the therapeutic window of glibenclamide was extended to 10 h after the onset of ischemia. This finding is consistent with observations in retrospective clinical studies showing that the use of sulfonylureas is beneficial in the setting of rt-PA-assisted recanalization / reperfusion after acute ischemic stroke (Simard, JM et al., Ann. NY Acad. Sci. 2012; 1268: 95-107).

[0525] In one embodiment, the combination is used to administer to a subject suffering from cardiogenic shock. Cardiogenic shock is a life-threatening medical condition caused by insufficient blood circulation due to the primary failure of the ventricles of the heart to function effectively. This condition occurs in 2% to 10% of patients hospitalized due to myocardial infarction and is the main cause of death in these patients (Holmes et al., 1995, J Am Coll Cardiol, 26: 668-674). More specifically, cardiogenic shock is the result of a complex process of oxygen delivery failure, systemic ATP deficiency, and multi-organ dysfunction caused by cardiac pump failure (Okuda, 2006, Shock, 25: 557-570). Since this is a circulatory shock, tissue perfusion is insufficient to meet the demand for oxygen and nutrients. Symptoms involve increasingly common cell death caused by insufficient oxygen (hypoxia) and insufficient nutrition (e.g., hypoglycemia). As such, it can lead to cardiac arrest (or circulatory arrest), which is a sudden cessation of the heart's pump function (as well as cessation of breathing and loss of consciousness). Cardiogenic shock is defined as persistent hypotension with inadequate tissue perfusion despite adequate left ventricular filling pressures. Signs of inadequate tissue perfusion include low urine output (<30 mL / hour), cooling of the extremities, and changes in consciousness level. Several large trials have demonstrated that coronary revascularization is the most important strategy to improve patient survival (Hochman et al., 1999, N Engl J Med, 341: 625-634). However, acute revascularization in patients who develop cardiogenic shock has a poor prognosis, which may be due to reperfusion injury and is believed to be related to infarct size. In fact, it has been demonstrated that hypothermia can provide tissue protection in myocardial ischemia, and preclinical studies have shown beneficial results in reducing infarct size in experimentally induced myocardial infarction (Dae et al., 2002, Am J Physiol Heart CircPhysiol, 282: H1584-H1591). Thus, in a porcine model, mild therapeutic hypothermia reduced acute mortality and improved hemodynamic parameters in cardiogenic shock (Gotberg et al., 2010, Resuscitation, 81: 1190-96).

[0526] In one embodiment, the combination is for administration to a subject suffering from cardiac arrest. Cardiac arrest is the sudden cessation of effective blood flow due to the inability of the heart to contract effectively. The most common cause of cardiac arrest is coronary artery disease. The treatment of cardiac arrest is immediate cardiopulmonary resuscitation (CPR) and, if a shockable heart rate is present, defibrillation. In the United States, approximately 13 out of every 10,000 people (326,000 cases) experience cardiac arrest outside of a hospital each year. Another 209,000 cases of cardiac arrest occur in hospitals (Kronic et al., Circulation, 2015, 132: S397-S413). In addition to providing high-quality cardiopulmonary resuscitation, optimizing the treatment of post-cardiac arrest syndrome is critical to improving the long-term outcomes of cardiac arrest patients. In this syndrome ("post-cardiac arrest syndrome"), there are three main areas of focus: (1) brain damage after cardiac arrest; (2) myocardial dysfunction and reperfusion injury after cardiac arrest; and (3) systemic ischemia-reperfusion response. It is now clear that postresuscitation care can influence long-term survival as well as myocardial and neurological recovery and function in survivors (Kern, 2015, Circ J, 79: 1156-1163).

[0527] In one embodiment, the subject is at risk for (or susceptible to) vascular occlusive injury or cardiac ischemia-reperfusion injury.

[0528] In one embodiment, the combination is for use in providing neuroprotection to a subject or for use in providing a method of neuroprotection to a subject.

[0529] As used herein, the term "neuroprotection" refers to protecting neural entities, including the brain, for example, by preventing, reducing or delaying brain damage that can lead to neuronal death and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease or vascular dementia.

[0530] In one embodiment, the combination is used to provide neuroprotection to a subject for the neurotoxic effects of a drug, or is used to provide a method for neuroprotection to a subject for the neurotoxic effects of a drug. Examples of neurotoxic drugs are described by Gouzoulis-Mayfrank and Daumann (Dialogues Clin Neurosci. 2009, 11 (3): 305-17). Neurotoxic drugs include abused drugs (e.g., 3,4-methylenedioxymethamphetamine, methamphetamine, and amphetamine), pesticides (e.g., based on organophosphorus pesticides), certain chemotherapies (e.g., platinum), and dopamine.

[0531] In one embodiment, the claimed combination is used to provide cardioprotection to a subject against the cardiotoxic effects of a drug (e.g., Acetone), or a method of providing cardioprotection to a subject against the cardiotoxic effects of a drug (e.g., Acetone). Examples of cardiotoxic drugs are described by Bovelli et al. (Annals of Oncology 21(Suppl 5): v277-v282, 2010).

[0532] As used herein, the term "cardioprotection" refers to protecting the heart, for example, by preventing, reducing or delaying myocardial damage. Cardiotoxic drugs include drugs associated with heart failure, drugs associated with ischemia or thromboembolism, drugs associated with hypertension, drugs associated with other toxic effects, such as tamponade and endomyocardial fibrosis, hemorrhagic myocarditis, bradyarrhythmias, Raynaud's phenomenon, autonomic neuropathy, QT prolongation or torsades depointes, or pulmonary fibrosis. Examples of cardiotoxic drugs include anthracyclines / anthraquinones, cyclophosphamide, trastuzumab and other monoclonal antibody-based tyrosine kinase inhibitors, antimetabolites (fluorouracil, capecitabine), antimicrotubule agents (paclitaxel, docetaxel), cisplatin, thalidomide, bevacizumab, sunitinib, sorafenib, busulfan, paclitaxel, vinblastine, bleomycin, vincristine, arsenic trioxide, bleomycin and methotrexate.

[0533] In one embodiment, the components are administered simultaneously.

[0534] In one embodiment, the components are administered sequentially or separately.

[0535] For a combination of three components, all three components may be administered simultaneously, or any two components may be administered simultaneously, with the third component administered separately or sequentially. Alternatively, all three components may be administered separately or sequentially in any order.

[0536] In one embodiment, the sulfonylurea is administered prior to sequential or separate administration of the insulin modulator.

[0537] In another embodiment, the insulin modulator is administered prior to the sequential or separate administration of the sulfonylurea.

[0538] In one embodiment, the sulfonylurea is administered prior to sequential or separate administration of the aldosterone antagonist.

[0539] In one embodiment, the aldosterone antagonist is administered prior to the sequential or separate administration of the sulfonylurea.

[0540] In one embodiment, exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; potassium canrenoate or a structural or functional analogue thereof; and glibenclamide or a structural or functional analogue thereof are administered sequentially or separately.

[0541] In one embodiment, each component is administered in a therapeutically effective amount relative to the individual components.

[0542] As used herein, the term "therapeutically effective amount" refers to an amount sufficient to achieve the desired therapeutic and / or preventive effect, such as an amount that results in prevention or reduction of ischemia and / or reperfusion injury or one or more symptoms associated with ischemia and / or reperfusion injury.

[0543] In the case of therapeutic or preventive applications, the amount of the composition administered to the subject will depend on the type and severity of the disease and the characteristics of the individual, such as general health, age, sex, body shape, weight and drug resistance. It will also depend on the severity and type of the disease. Those skilled in the art will be able to determine the appropriate dosage based on these and other factors. The composition may also be administered in combination with one or more other therapeutic agents.

[0544] In one embodiment, each component is administered in a subtherapeutically effective amount relative to the individual components.

[0545] In one embodiment, the components are administered prior to reperfusion of the subject.

[0546] In one embodiment, the components are administered during reperfusion of the subject.

[0547] In one embodiment, the components are administered after reperfusion of the subject.

[0548] In one embodiment, the components are administered before and / or during and / or after reperfusion of the subject.

[0549] In some embodiments of the methods, the sulfonylurea is administered to the subject continuously before, during, and after reperfusion of the subject, and the insulin regulator is administered to the subject as a bolus dose prior to reperfusion.

[0550] In some embodiments of the methods, the insulin regulator is administered to the subject continuously before, during, and after reperfusion of the subject, and the sulfonylurea is administered to the subject as a bolus dose prior to reperfusion.

[0551] In some embodiments of the methods, the sulfonylurea is administered to the subject continuously before, during, and after reperfusion of the subject, and the aldosterone antagonist is administered to the subject as a bolus dose prior to reperfusion.

[0552] In some embodiments of the methods, the aldosterone antagonist is administered to the subject continuously before, during, and after reperfusion of the subject, and the sulfonylurea is administered to the subject as a bolus dose prior to reperfusion.

[0553] In some embodiments of the methods, the components are administered to the subject continuously before, during, and after reperfusion of the subject.

[0554] In some embodiments of the method, there may be additional administration of one or more components after reperfusion. Preferably, the repeated administration is performed at least twice, more preferably 2 to 100 times, or may be performed in the form of continuous infusion.

[0555] In some embodiments of the methods, each component is administered to the subject as a bolus dose prior to reperfusion.

[0556] In some embodiments of the methods, each component is administered to the subject as a bolus dose during reperfusion.

[0557] In some embodiments of the methods, each component is administered to the subject as a bolus dose following reperfusion.

[0558] As used herein, "reperfusion" is the restoration of blood flow to any organ or tissue to which blood flow is reduced or blocked. For example, blood flow can be restored to any organ or tissue affected by ischemia or hypoxia. Restoration of blood flow (reperfusion) can be achieved by any method known to those skilled in the art. For example, reperfusion of ischemic cardiac tissue can be achieved by revascularization.

[0559] In one embodiment, reperfusion is achieved by a revascularization procedure. In one embodiment, the revascularization procedure is selected from the group consisting of: percutaneous coronary intervention; balloon angioplasty; bypass graft implantation; stent implantation; directional coronary atherectomy; treatment with one or more thrombolytic agents; and blockage removal.

[0560] In one embodiment, the one or more thrombolytic agents are selected from the group consisting of: tissue plasminogen activator; urokinase; prourokinase; streptokinase; acylated forms of plasminogen; acylated forms of plasmin; and acylated streptokinase-plasminogen complex.

[0561] dose

[0562] Those of ordinary skill in the art can easily determine the appropriate dosage for applying one of the compositions of the present invention to a subject without excessive experimentation. Typically, the physician will determine the actual dosage that is most suitable for the individual patient, and this will depend on various factors, including the activity of the specific compound used, the metabolic stability and duration of action of the compound, age, body weight, general health, sex, diet, mode and time of administration, excretion rate, drug combination, severity of specific illness, and the individual being treated. The dosage disclosed herein is an example of an average situation. Of course, there may be individual cases with higher or lower dosage ranges, which are all within the scope of the present invention.

[0563] In a highly preferred embodiment of the invention, the dose of the insulin modulator (e.g., exenatide) in the combination is typically lower than the dose typically used in monotherapy in currently approved therapies and / or lower than the typical dose reported in the reperfusion injury literature.

[0564] In a highly preferred embodiment of the invention, the dose of the aldosterone antagonist (e.g., potassium canrenoate) in the combination is generally lower than the dose typically used in monotherapy in currently approved therapies and / or lower than the typical dose reported in the reperfusion injury literature.

[0565] In a highly preferred embodiment of the invention, the dose of the sulfonylurea (eg, glibenclamide) in the combination is generally lower than the dose typically used in monotherapy in currently approved therapies and / or lower than typical doses reported in the reperfusion injury literature.

[0566] Each component of the claimed combination may be formulated in unit dosage form, ie in the form of discrete portions containing a unit dose or multiple unit doses or subunits of a unit dose. The dosages described herein may be used for each of the above-mentioned medical uses.

[0567] When used in the combination claimed in the present invention, the insulin regulator (e.g., exenatide) is preferably administered at a dose of about 0.001 μg / kg to about 1.5 μg / kg, more preferably about 0.005 μg / kg to about 0.15 μg / kg. In a preferred embodiment, the insulin regulator (e.g., exenatide) is preferably administered at a dose of about 0.01 μg / kg to about 1.5 μg / kg, more preferably about 0.05 μg / kg to about 1.5 μg / kg. As used herein, the insulin regulator dose is in μg / kg body weight (μg = microgram).

[0568] In a preferred embodiment, the insulin modulator (e.g., exenatide) is preferably administered at a dose of about 0.01 μg / kg to about 0.5 μg / kg, more preferably about 0.02 μg / kg to about 0.5 μg / kg, or about 0.03 μg / kg to about 0.5 μg / kg, or about 0.04 μg / kg to about 0.5 μg / kg, or about 0.05 μg / kg to about 0.5 μg / kg, or about 0.05 μg / kg to about 0.2 μg / kg, or about 0.05 μg / kg to about 0.15 μg / kg.

[0569] In a preferred embodiment, the insulin modulator (e.g., exenatide) is preferably administered at a dose of about 0.01 μg / kg to about 0.1 μg / kg, more preferably about 0.02 μg / kg to about 0.08 μg / kg, or about 0.03 μg / kg to about 0.07 μg / kg, or about 0.04 μg / kg to about 0.06 μg / kg, or about 0.05 μg / kg.

[0570] When used in the combination claimed in the present invention, the aldosterone antagonist (e.g., potassium canrenoate) is preferably administered at a dose of about 0.03 mg / kg to about 10 mg / kg, or about 0.1 mg / kg to about 10 mg / kg, or about 0.3 mg / kg to about 5 mg / kg, or about 1 mg / kg to about 10 mg / kg, or about 1 mg / kg to about 5 mg / kg, or about 1 mg / kg to about 3 mg / kg. As used herein, the aldosterone antagonist dose is in mg / kg body weight.

[0571] In a preferred embodiment, the aldosterone antagonist (e.g., potassium canrenoate) is preferably administered at a dose of about 0.1 mg / kg to about 3 mg / kg, or about 0.2 mg / kg to about 2 mg / kg, or about 0.3 mg / kg to about 1.5 mg / kg, or about 0.3 mg / kg to about 1 mg / kg.

[0572] In a preferred embodiment, the aldosterone antagonist (e.g., potassium canrenoate) is preferably administered at a dose of about 0.1 mg / kg to about 0.5 mg / kg, or about 0.2 mg / kg to about 0.5 mg / kg, more preferably about 0.2 mg / kg to about 0.4 mg / kg, even more preferably about 0.3 mg / kg to 0.4 mg / kg.

[0573] When used in the combination claimed in the present invention, the sulfonylurea (e.g., glibenclamide) is preferably administered at a dosage of about 0.001 μg / kg to about 30 μg / kg, more preferably about 0.01 μg / kg to about 5 μg / kg, even more preferably about 0.01 μg / kg to about 2 μg / kg. The sulfonylurea dosages used herein are in μg / kg body weight.

[0574] In a preferred embodiment, the sulfonylurea (e.g., glibenclamide) is preferably administered at a dose of about 0.5 μg / kg to about 20 μg / kg, or about 0.5 μg / kg to about 15 μg / kg, or about 0.5 μg / kg to about 10 μg / kg, or about 1 μg / kg to about 10 μg / kg.

[0575] In a preferred embodiment, sulfonylurea (e.g., glibenclamide) is preferably administered at a dosage of about 0.5 μg / kg to about 8 μg / kg, or about 0.5 μg / kg to about 7 μg / kg, or about 0.5 μg / kg to about 6 μg / kg, or about 0.5 μg / kg to about 5 μg / kg. In a preferred embodiment, sulfonylurea (e.g., glibenclamide) is preferably administered at a dosage of about 0.5 μg / kg to about 3 μg / kg, or about 0.5 μg / kg to about 2 μg / kg, or about 0.5 μg / kg to about 1.5 μg / kg, or about 0.8 μg / kg to about 1.2 μg / kg, or about 1 μg / kg.

[0576] In a highly preferred embodiment, the combination is a fixed dose combination comprising predetermined doses of the respective pharmaceutically active ingredients, e.g. to allow administration of the above doses to a subject, e.g. about 0.005 μg / kg to about 0.15 μg / kg of exenatide and about 0.001 μg / kg to about 30 μg / kg of glibenclamide.

[0577] Preferably, the fixed dose combination comprises predetermined doses of the respective pharmaceutically active ingredients to allow the following doses to be administered to a subject.

[0578] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.01 μg / kg to about 0.5 μg / kg of exenatide and from about 0.5 μg / kg to about 20 μg / kg of glibenclamide.

[0579] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.01 μg / kg to about 0.1 μg / kg of exenatide and from about 0.5 μg / kg to about 8 μg / kg of glibenclamide.

[0580] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.01 μg / kg to about 0.1 μg / kg of exenatide and from about 0.5 μg / kg to about 1.5 μg / kg of glibenclamide.

[0581] In a highly preferred embodiment, the combination is a fixed dose combination comprising predetermined doses of the respective components, for example, from about 0.03 mg / kg to about 10 mg / kg potassium canrenoate and from about 0.001 μg / kg to about 30 μg / kg glibenclamide.

[0582] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.1 mg / kg to about 3 mg / kg potassium canrenoate and from about 0.5 μg / kg to about 20 μg / kg glibenclamide.

[0583] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.1 mg / kg to about 0.5 mg / kg potassium canrenoate and from about 0.5 μg / kg to about 8 μg / kg glibenclamide.

[0584] In a highly preferred embodiment, the combination is a fixed dose combination comprising from about 0.1 mg / kg to about 0.5 mg / kg potassium canrenoate and from about 0.5 μg / kg to about 1.5 μg / kg glibenclamide.

[0585] In a highly preferred embodiment, the combination is a fixed dose combination comprising predetermined doses of the respective components, e.g., about 0.03 mg / kg to about 10 mg / kg potassium canrenoate, about 0.001 μg / kg to about 30 μg / kg glibenclamide, and about 0.005 μg / kg to about 0.15 μg / kg exenatide.

[0586] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.1 mg / kg to about 3 mg / kg potassium canrenoate, about 0.5 μg / kg to about 20 μg / kg glibenclamide, and about 0.01 μg / kg to about 0.5 μg / kg exenatide.

[0587] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.1 mg / kg to about 0.5 mg / kg potassium canrenoate, about 0.5 μg / kg to about 8 μg / kg glibenclamide, and about 0.01 μg / kg to about 0.1 μg / kg exenatide.

[0588] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.1 mg / kg to about 0.5 mg / kg potassium canrenoate, about 0.5 μg / kg to about 1.5 μg / kg glibenclamide, and about 0.01 μg / kg to about 0.1 μg / kg exenatide.

[0589] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.05 μg / kg exenatide and 1 μg / kg glibenclamide.

[0590] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.33 mg / kg potassium canrenoate and about 1 μg / kg glibenclamide.

[0591] In a highly preferred embodiment, the combination is a fixed dose combination comprising about 0.05 μg / kg exenatide, about 0.33 mg / kg potassium canrenoate and about 1 μg / kg glibenclamide.

[0592] Non-therapeutic use

[0593] In another aspect, the present invention relates to the use of a combination for treating and / or preventing ischemia and / or reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0594] (a) sulfonylureas; and

[0595] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0596] In another preferred embodiment, the present invention relates to the use of a combination for treating and / or preventing ischemia and / or reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0597] (a) glibenclamide or a structural or functional analogue thereof; and

[0598] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0599] In one embodiment, the present invention relates to the use of a combination for treating and / or preventing reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0600] (a) sulfonylureas; and

[0601] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0602] In a preferred embodiment, the present invention relates to the use of a combination for treating and / or preventing reperfusion injury of an isolated organ before or during transplantation, the combination comprising:

[0603] (a) glibenclamide or a structural or functional analogue thereof; and

[0604] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; (ii) potassium canrenoate, or a structural or functional analogue thereof.

[0605] In one embodiment, the invention relates to the use of a combination for treating and / or preventing ischemia of an isolated organ before or during transplantation, the combination comprising:

[0606] (a) sulfonylureas; and

[0607] (b) at least one of the following: (i) an insulin modulator and (ii) an aldosterone antagonist.

[0608] In a preferred embodiment, the present invention relates to the use of a combination for treating and / or preventing ischemia of an isolated organ before or during transplantation, the combination comprising:

[0609] (a) glibenclamide or a structural or functional analogue thereof; and

[0610] (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate or a structural or functional analogue thereof.

[0611] An ex vivo (removed from the body) organ may be susceptible to reperfusion injury due to lack of blood flow. Therefore, the combination of the present invention can be used to prevent reperfusion injury of the removed organ. Preferably, the organ is the heart, liver or kidney, more preferably the heart.

[0612] In some embodiments, the removed organ is placed in a standard buffer solution containing the combination of the present invention, such as a buffer solution commonly used in the art containing the combination of the present invention. For example, the removed heart can be placed in a cardioplegia solution containing exenatide, potassium canrenoate and glibenclamide. Those skilled in the art can easily determine the concentration of exenatide, potassium canrenoate and glibenclamide used in the standard buffer solution. Such a concentration can be, for example, between about 0.1 nM and about 10 μM, preferably about 1 nM to about 10 μM.

[0613] The invention is further described with reference to the accompanying non-limiting examples and the following figures, in which:

[0614] Figure 1Shown are relative cerebral infarct volumes (%) of the low-dose triple combination (treatment S) compared to control animals in Parts I and II and in animals receiving the corresponding monotherapy (treatments A, E and I) and the corresponding double combination (treatments M, N and O) on day 7 after repeated administration (7 days) in a rat model of transient middle cerebral artery occlusion. Treatment A: Exenatide 0.05 μg / kg (n=4); Treatment E: Canrenoate potassium 0.33 mg / kg (n=3); Treatment I: Glibenclamide 1 μg / kg (n=4); Treatment M: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg (n=13); Treatment N: Exenatide 0.05 μg / kg and Glibenclamide 1 μg / kg (n=12); Treatment O: Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=11); Treatment S: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=7). Control part I (n=6); Control animal part II (n=5).

[0615] Figure 2 Shown are altered neurological severity scores on day 2 after repeated administration (7 days) of the low-dose triple combination (treatment S) compared to control animals in Parts I and II and in animals receiving the corresponding monotherapy (treatments A, E, and I) and the corresponding dual combination (treatments M, N, and O) in the transient middle cerebral artery occlusion rat model. Treatment A: Exenatide 0.05 μg / kg (n=4); Treatment E: Canrenoate potassium 0.33 mg / kg (n=3); Treatment I: Glibenclamide 1 μg / kg (n=4); Treatment M: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg (n=13); Treatment N: Exenatide 0.05 μg / kg and Glibenclamide 1 μg / kg (n=12); Treatment O: Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=11); Treatment S: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=7). Control part I (n=6); Control animal part II (n=5).

[0616] Figure 3Shown are altered neurological severity scores for the low-dose triple combination (treatment S) compared to control animals in Part I and Part II and in animals receiving the corresponding monotherapy (treatments A, E, and I) and the corresponding dual combination (treatments M, N, and O) on day 7 after repeated administration (7 days) in a rat model of transient middle cerebral artery occlusion. Treatment A: Exenatide 0.05 μg / kg (n=4); Treatment E: Canrenoate potassium 0.33 mg / kg (n=3); Treatment I: Glibenclamide 1 μg / kg (n=4); Treatment M: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg (n=13); Treatment N: Exenatide 0.05 μg / kg and Glibenclamide 1 μg / kg (n=12); Treatment O: Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=11); Treatment S: Exenatide 0.05 μg / kg and Canrenoate potassium 0.33 mg / kg and Glibenclamide 1 μg / kg (n=7). Control part I (n=6); Control animal part II (n=5).

[0617] Figure 4 Relative cerebral infarct volume (%) of the higher dose triple combination (treatment T) compared to control animals in Part I and Part II and in animals receiving the corresponding monotherapy (treatments B, F and K) and the corresponding double combination (treatments Q and R) on day 7 after repeated administration (7 days) in a rat model of transient middle cerebral artery occlusion is shown. Treatment B: exenatide 0.15 μg / kg (n=8); Treatment F: canrenoate potassium 1 mg / kg (n=8); Treatment K: glibenclamide 10 μg / kg (n=8); Treatment Q: exenatide 0.15 μg / kg and glibenclamide 10 μg / kg (n=4); Treatment R: canrenoate potassium 1 mg / kg and glibenclamide 10 μg / kg (n=5); Treatment T: exenatide 0.15 μg / kg and canrenoate potassium 1 mg / kg and glibenclamide 10 μg / kg (n=7). Control part I (n=6); control animals part II (n=5).

[0618] Figure 5Shown are altered neurological severity scores in the transient middle cerebral artery occlusion rat model at day 2 after repeated administration (7 days) for the higher dose triple combination (treatment T) compared to control animals in Part I and Part II and animals receiving the corresponding monotherapy (treatments B, F and K) and the corresponding double combination (treatments Q and R). Treatment B: Exenatide 0.15 μg / kg (n=8); Treatment F: Canrenoate potassium 1 mg / kg (n=8); Treatment K: Glibenclamide 10 μg / kg (n=8); Treatment Q: Exenatide 0.15 μg / kg and Glibenclamide 10 μg / kg (n=4); Treatment R: Canrenoate potassium 1 mg / kg and Glibenclamide 10 μg / kg (n=5); Treatment T: Exenatide 0.15 μg / kg and Canrenoate potassium 1 mg / kg and Glibenclamide 10 μg / kg (n=7). Control part I (n=6); control animals part II (n=5).

[0619] Figure 6 Shown are altered neurological severity scores in the transient middle cerebral artery occlusion rat model at day 7 after repeated administration (7 days) for the higher dose triple combination (treatment T) compared to control animals in Part I and Part II and in animals receiving the corresponding monotherapy (treatments B, F and K) and the corresponding dual combination (treatments Q and R). Treatment B: Exenatide 0.15 μg / kg (n=8); Treatment F: Canrenoate potassium 1 mg / kg (n=8); Treatment K: Glibenclamide 10 μg / kg (n=8); Treatment Q: Exenatide 0.15 μg / kg and Glibenclamide 10 μg / kg (n=4); Treatment R: Canrenoate potassium 1 mg / kg and Glibenclamide 10 μg / kg (n=5); Treatment T: Exenatide 0.15 μg / kg and Canrenoate potassium 1 mg / kg and Glibenclamide 10 μg / kg (n=7). Control part I (n=6); control animals part II (n=5).

[0620] Figure 7 The results of histological TUNEL staining of apoptosis in the hippocampus of rats treated with the triple combination of exenatide / canrenoate potassium / glibenclamide in a vascular dementia rat model are shown. More specifically, Figure 7 Shown are the percentages of apoptotic cells (mean ± SEM) in rats treated with 0.05 μg / kg exenatide + 0.33 mg / kg potassium canrenoate + 1 μg / kg glibenclamide (2M group; 13 animals; intravenous administration) compared to vehicle-treated controls (1M group; 9 animals).

[0621] Example

[0622] The present invention is further illustrated by the following examples, which should not be construed as limiting in any way.

[0623] Example 1. Dose-effect study of the efficacy of exenatide, potassium canrenoate, glibenclamide and their combination in a rat cerebral ischemia and reperfusion injury model

[0624] The objectives of this study were to evaluate (a) the dose effect of glibenclamide, exenatide, and potassium canrenoate in a rat model of cerebral ischemia and reperfusion injury after repeated intravenous administration as monotherapy (Study Part I) and (b) the effects of combinations of compounds compared to the corresponding monotherapy (Study Part II).

[0625] Temporary middle cerebral artery occlusion (t-MCAO) was performed according to the method described by R. Schmid-Elsaesser et al. (Stroke. 1998; 29 (10): 2162-70). The test compound was administered intravenously 20 minutes before reperfusion and then twice daily for six consecutive days thereafter. On the second day of the study (one day after surgery) and the seventh day of the study (7 days after surgery and before the termination of the study), the altered neurological severity score (NSS) was graded from 0 to 18 points (where normal score is 0 and the maximum deficit score is represented by 18); it includes a set of clinical neurological tests (a combination of motor, sensory, reflex and balance tests). At the end of the study, the brain was collected, cut into five 2 mm thick coronal sections, and stained with triphenyltetrazolium chloride (TTC) to measure the infarct size using the ImageJ program. Morbidity, mortality, body weight and clinical observations were also recorded. Numerical results are shown as mean ± standard deviation of the mean. Statistical significance (P) of the treated groups compared to the untreated control group was determined using two-way ANOVA followed by the Bonferroni post hoc test using the GraphPad Prism 5 program.

[0626] In study part I, a total of 112 SD male rats (270 gr to 320 gr upon arrival) were divided into 13 groups (5 or 10 rats per treatment group and 8 rats in the control group). Due to mortality in some groups, the number within each group was adjusted to have enough animals in all groups. The groups were as follows:

[0627] Control (saline)

[0628] Exenatide was administered at 0.05 μg / kg, 0.15 μg / kg, 0.5 μg / kg, and 1.5 μg / kg;

[0629] Potassium canrenoate was administered at 0.33 mg / kg, 1 mg / kg, 3 mg / kg, and 10 mg / kg;

[0630] Glyburide was administered at 1 μg / kg, 3 μg / kg, 10 μg / kg and 30 μg / kg.

[0631] The results of the efficacy endpoints obtained in Part I are summarized in Table 1 and are also expressed as a percentage change compared to the corresponding control, including statistical comparisons of each treatment compared to the corresponding control group. Twenty-seven animals died during the study period in all groups (1 died during surgery, 5 died after occlusion, 1 was euthanized on day 2, 7 died shortly after reperfusion, and 13 were found dead in their cages within one to five days after surgery). There were no statistically significant differences in body weight between all animal groups.

[0632] All monotherapy treatments except the lowest dose of exenatide, potassium canrenoate, and glyburide (treatments A, E, and I) showed statistically significant reductions in infarct size compared with the control group. There was no clear evidence of a dose effect.

[0633] Regarding the changed neurological severity score (NSS), only the lowest dose of exenatide, potassium canrenoate, and glibenclamide (treatments A, E, and I) and glibenclamide at 3 μg / kg (treatment J) did not show a statistically significant reduction compared to the control group on day 2, while only the lowest dose of exenatide, potassium canrenoate, and glibenclamide (treatments A, E, and I) and exenatide at 0.5 μg / kg (treatment C) did not show a statistically significant reduction compared to the control group on day 7. As with the case of infarct size, for the changed NSS, there was no clear evidence of a dose effect on both days 2 and 7.

[0634] In study part II, a total of 86 SD male rats (270 gr to 320 gr upon arrival) were divided into 9 groups (7 or 15 rats per treatment group and 6 rats in the control group). Due to mortality in some groups, the number within each group was adjusted to have enough animals in all groups. The groups were as follows:

[0635] Control (saline)

[0636] Exenatide was administered at 0.05 μg / kg, and potassium canrenoate was administered at 0.33 mg / kg;

[0637] Exenatide was administered at 0.05 μg / kg, and glyburide was administered at 1 μg / kg;

[0638] Potassium canrenoate was administered at 0.33 mg / kg, and glibenclamide was administered at 1 μg / kg;

[0639] Exenatide was administered at 0.15 μg / kg, and potassium canrenoate was administered at 0.33 mg / kg;

[0640] Exenatide was administered at 0.15 μg / kg, and glyburide was administered at 10 μg / kg;

[0641] Potassium canrenoate was administered at 1 mg / kg, and glibenclamide was administered at 10 μg / kg;

[0642] Exenatide was administered at 0.05 μg / kg, and potassium canrenoate was administered at 0.33 mg / kg, and glyburide was administered at 1 μg / kg;

[0643] Exenatide was administered at 0.15 μg / kg, and potassium canrenoate was administered at 1 mg / kg, and glibenclamide was administered at 10 μg / kg.

[0644] The results of the efficacy endpoints obtained in Part II are summarized in Table 2 and are also expressed as percentage changes relative to the corresponding controls, including statistical comparisons of each treatment compared to the corresponding control group. During the study period of all groups, nineteen animals died (2 were euthanized on Day 6, 4 died shortly after reperfusion, and 13 were found dead in their cages within one to five days after surgery). There were no statistically significant differences in body weight between all animal groups.

[0645] When compared with the control group, all the dual combinations (groups M, N, O, P, Q, and R) and triple combinations (groups S and T) showed statistically significant changes in brain infarct size. There were no differences between dual doses (groups M, N, O, P, Q, and R) or triple dose combinations (groups S and T). After the administration of the lowest dose of the dual combination of exenatide and potassium canrenoate (group M), the reduction in brain infarct size was statistically different from the reduction in brain infarct size after the corresponding monotherapy (groups A and E). After the administration of the lowest dose of the dual combination of exenatide and glibenclamide (group N), the reduction in brain infarct size was only statistically different from the corresponding glibenclamide monotherapy (group I). In addition, the lowest dose (group S) but not the higher dose (group T) of the triple combination showed statistical significance in the reduction of brain infarct size compared with the corresponding monotherapy.

[0646] When compared to the control group, all dual combinations (Groups M, N, O, P, Q, and R) and two triple combinations (Groups S and T) showed statistically significant reductions in the changed neurological severity score (NSS) at both Day 2 and Day 7. In addition, the reduction in changed NSS using the lowest dose of the triple combination of exenatide, potassium canrenoate, and glibenclamide (Group S) was statistically significantly different from the corresponding potassium canrenoate and glibenclamide monotherapy (Groups E and I) on Day 2, and significantly different from all three corresponding monotherapy (Groups A, E, and I) on Day 7, but not significantly different from any of the corresponding dual combinations (Groups M, N, and O). The higher dose of the triple combination of exenatide, potassium canrenoate, and glibenclamide (Group T) was not statistically significantly different from any of the corresponding dual combinations (Groups Q and R).

[0647] To evaluate the effect of combined treatment, Figures 1 to 3 The lowest dose of the triple combination (treatment "S") is compared with the corresponding monotherapy and dual combination in terms of relative infarct volume and altered neurological severity scores at day 2 and day 7, respectively. Similarly, the higher dose of the triple combination (treatment "T") is compared with the corresponding monotherapy and dual combination in terms of relative infarct volume and altered neurological severity scores at day 2 and day 7, respectively. Figures 4 to 6 middle.

[0648] It is clear from the results obtained that low doses of exenatide, potassium canrenoate and glibenclamide, which are ineffective when administered as monotherapy, show statistically significant efficacy when they are combined (as a double or triple combination), indicating a synergistic effect. The results of the present invention provide strong evidence that the combination therapy of glibenclamide with exenatide and / or potassium canrenoate acts in a synergistic manner.

[0649] Reduced the severity of cerebral infarction and / or

[0650] Improved neurological severity scores and / or

[0651] Improved motor behavior scores,

[0652] This is because the combined effect obtained exceeds the sum of the effects of each monotherapy. In addition, it was surprisingly found that the dose of glibenclamide (i.e. 1 μg / kg twice a day, 0.66 μg for rats weighing 330 g used in the study) that produced this synergistic effect in the present study was significantly lower than the dose reported in the previous literature for stroke, i.e. 200 ng / h infused daily, i.e. 4.8 μg (Simard et al., Transl Stroke Res. 2012). Importantly, in the case of the present invention, this very low dose of glibenclamide is equivalent to such a dose (i.e. 70 μg / day), which is 100 times lower than the defined daily dose (micronized preparation oral 7 mg) or about 20 to 285 times lower than the recommended maintenance dose of glibenclamide (micronized preparation), so it is expected that the dose has no effect on blood glucose levels or has no side effects. The above clinically effective dose of glibenclamide as a dual or triple combination with low-dose exenatide and / or potassium carbonate is also significantly lower than the dose of glibenclamide that has been shown to have a neuroprotective effect in clinical studies disclosed in the literature (0.16 mg / h or 0.11 mg / h continuous infusion, i.e. 3.84 mg or 2.64 mg per day) (see King ZA et al.).

[0653] Example 2. Study on the efficacy of the combination of exenatide, potassium canrenoate and glibenclamide in a rat model of vascular dementia

[0654] The chronic cerebral hypoperfusion model in Wistar rats, which induces brain damage in the rat brain by permanently occluding both common carotid arteries, also produces cognitive deficits. This model is similar to that of vascular dementia, and the technique can reduce blood flow in the cerebral cortex and hippocampus by as much as 40% to 80% for several months, inducing certain learning impairments.

[0655] Purpose

[0656] The aim of this study was to evaluate the neuroprotective efficacy of a combination of exenatide, potassium canrenoate and glibenclamide, given intravenously 24 hours after permanent ligation of both common carotid arteries and then twice daily for three weeks, using the Vestal rat model of vascular dementia.

[0657] Treatment Group

[0658] The treatment groups were as follows:

[0659] Group 1M: vehicle-treated control (9 animals, intravenous administration);

[0660] Group 2M: Exenatide 0.05 μg / kg + potassium canrenoate 0.33 mg / kg + glibenclamide 1 μg / kg (13 animals; intravenous administration).

[0661] Exenatide acetate was obtained from Bachem AG, Switzerland. Canrenoate potassium was obtained from Pfizer, Switzerland. Glyburide was obtained from Tocris Bioscience.

[0662] Study design and timeline

[0663] This study evaluated the neuroprotective effects of a combination of low-dose intravenous administration twice a day for three weeks in a Wistar rat vascular dementia model. Test compounds were administered twice a day 24 hours after common carotid artery ligation for three weeks. On day 1, both common carotid arteries were permanently ligated. Morris water maze tests were performed as baseline training before common carotid artery ligation and Morris water maze tests were performed at weeks 4 and 8 thereafter. At the end of the study, brains were collected. Tissues were subjected to histological analysis. The study timeline is as follows:

[0664]

[0665] CCAO = common carotid artery occlusion; D = day; W = week; BW = body weight; MWM = Morris water maze

[0666] The first dosing day was designated as "Day 1," and the end point was "Day 56," eight weeks after common carotid artery ligation.

[0667] Histological analysis

[0668] Tissue preparation and trimming (affected hemisphere), X3 precise sections of the striatum (corpus callosum), dorsal hippocampus and optic nerve per brain. Paraffin block preparation H&E and TUNEL staining, IHC: Doublecortin for neurogenesis in the subventricular zone. MBP (myelin in white matter), Iba-1 for microglia and GFAP for astrocytes. Olig-2 for all oligodendrocytes and NG2 for young oligodendrocytes. Slice evaluation analysis; cell body counts in the CA1 and CA3 regions of the hippocampus - three slices per brain, three fields per slice; morphometric analysis of neuronal death counts and MBP.

[0669] animal

[0670] Male Wistar rats weighing 290 g to 390 g at the start of the study were used in the study.

[0671] Animal Management

[0672] live

[0673] Animal handling was performed in accordance with the guidelines of the National Institutes of Health (NIH) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Animals were housed in polyethylene cages (maximum 3 rats / cage) measuring 42.5 cm × 26.5 cm × 18.5 cm with a stainless steel top grid for easy access to pelleted food and drinking water in plastic bottles; bedding: steam sterilized clean rice husks (Envigo, Sani-chips cat#7090C). Bedding materials were changed at least twice a week along with the cages.

[0674] diet

[0675] Animals were fed a commercial rodent diet (Teklad Certified Global 18% Protein Diet, Envigocat #2018SC) ad libitum. Animals had free access to standard potable tap water obtained from a municipal supply and treated according to Pharmaseed's SOP No. 214 "Water Systems". Animal feed came with a certificate of analysis and water was autoclaved before use.

[0676] Environmental conditions

[0677] For a period of time after surgery, the animals were housed individually in a climate-controlled environment. The air was filtered (HEPA F6 / 6) and provided with an ample fresh supply (minimum 15 air changes / hour). The temperature was maintained at 18°C ​​to 24°C and the relative humidity was maintained at 30% to 70%. The animals were exposed to a 12-hour light and 12-hour dark cycle (6AM / 6PM).

[0678] Randomization

[0679] Animals were randomly assigned to cages according to Pharmaseed's SOP #027 "Randomization of Animals".

[0680] Surgery and evaluation

[0681] Surgical procedure: Bilateral common carotid artery ligation

[0682] On the day of surgery, anesthesia was induced with a mixture of 70% N2O and 30% O2 containing 4% isoflurane on a heating pad and maintained with 1.5% to 2% isoflurane. 0.1 mg / kg buprenorphine was injected subcutaneously. Two common carotid arteries were occluded according to the method described by Hyun Joon Lee et al. (Citicoline Protects Against Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion, J Clin Neurol. 2009; 5(1): 33-38). The two common carotid arteries (CCA) were exposed through a midline cervical incision and carefully cut to separate them from the surrounding nerves and fascia. Both arteries were double ligated with 4-0 silk sutures 8 mm to 10 mm below the visible area of ​​the external carotid artery. The surgical wound was closed and the animals were returned to their cages to recover from anesthesia. At the end of the day, analgesia was again given with buprenorphine and during the next four days, analgesia was given with buprenorphine twice daily.

[0683] Combined administration

[0684] Treatment was given by intravenous (IV) injection starting 24 hours after arterial ligation and was given twice daily for three consecutive weeks.

[0685] weight

[0686] The body weight of the animals was monitored during the acclimation period, before common carotid artery ligation, and twice a week thereafter. The animals were weighed according to Pharmaseed's SOP No. 010 "Weighing Laboratory Animals". Individual body weight changes were calculated.

[0687] Clinical observation

[0688] Monitor clinical signs once during the acclimation period, once within the first 4 hours after surgery, twice a day during the first two days after surgery, and then twice a week thereafter.

[0689] Morris water maze test

[0690] The Morris water maze (MWM) test is designed to evaluate cognitive deficits after common carotid artery ligation. The test was performed according to SOP100 (Morris water maze test V6) of Pharmaseed and related publications (e.g., Brandeis R, Brandys Y, and Yehuda S, "The use of the Morris Water Maze in the study of memory and learning", Int J Neurosci. 1989; 48 (1-2): 29-69).

[0691] Preoperative training

[0692] Animals were trained and conditioned in the Morris water maze for one week according to Pharmaseed's SOP 100 and scientific publications (e.g., see Brandeis R et al.) Prior to MWM, the rats' cages were transferred from the animal room to the behavioral testing room and acclimated for approximately one hour.

[0693] The results of the last day of training were considered as baseline data for comparison. The MWM test had the following exclusion criteria: failure to escape to the platform within 90 seconds (on the 3rd day of training).

[0694] Common carotid artery ligation test

[0695] Prior to MWM, rats were transferred from their cages in the animal room to the behavioral testing room and allowed to acclimate for approximately one hour.

[0696] MWM test was performed at 4 and 8 weeks after common carotid artery ligation.

[0697] Statistical analysis

[0698] Numerical results are given as mean values ​​and standard deviations or standard errors. Whenever possible, descriptive statistics and group comparisons of data were performed using a statistical analysis program (GraphPad Prism Version 5.02 for Windows, GraphPad Software, San Diego, California, USA). Appropriate parametric or nonparametric tests were performed, followed by appropriate post hoc analyses. A probability of 5% (p≤0.05) was considered statistically significant.

[0699] result

[0700] Preliminary results of the MWM test showed that animals treated with the triple combination of exenatide / canrenoate / glibenclamide (treatment group 2M; 13 animals) performed better than those treated with vehicle (1M group; 9 animals) in terms of the average time (seconds) taken to reach the platform and the average distance (cm) swam to the platform. In addition, quantitative evaluation of histological TUNEL staining for apoptosis in the hippocampus showed that treatment group 2M had a statistically significant neuroprotective effect relative to group 1M (vehicle) (at p = 0.03, according to the Mann-Whitney test). Figure 7 The percentage of apoptotic cells in each group is shown (mean ± SEM).

[0701] Therefore, it can be concluded that the triple combination of exenatide / canrenoate potassium / glyburide showed neuroprotective effects in the Wistar rat vascular dementia model when administered intravenously at low doses twice a day for three weeks, demonstrating improved cognitive behavior and reduced apoptosis in the hippocampal brain region.

[0702] Without departing from the scope and spirit of the present invention, various modifications and variations of the aspects of the present invention will be apparent to those skilled in the art. Although the present invention has been described in conjunction with specific preferred embodiments, it should be understood that the claimed invention should not be overly limited by these specific embodiments. In fact, various modifications to the described modes of implementing the present invention that are apparent to those skilled in the relevant art are intended to fall within the scope of the appended claims.

[0703] References

[0704] Abdallah DM, et al. Glibenclamide ameliorates ischemia-reperfusioninjury via modulating oxidative stress and inflammatory mediators in the rathippocampus. Brain Res. 2011;1385:257-62.

[0705] Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019; 103: 263-293.

[0706] Bai J, Lyden PD. Revisiting cerebral post-ischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. Int J Stroke. 2015;10:143 - 52.

[0707] Battistin L, Cagnin A(2010.12). "Vascular cognitive disorder. A biological and clinical overview". Neurochemical Research. 35(12):1933 - 8. doi:10.1007 / s11064 - 010 - 0346 - 5. PMID 21127967.

[0708] Brandeis R, Brandys Y and Yehuda S, “The use of the Morris Water Maze in the study of memory and learning”, Int J Neurosci. 1989;48(1 - 2):29 - 69.

[0709] Berge SM, et al. Pharmaceutical salts. J Pharm Sci. 1977;66:1 - 19.

[0710] Beygui F, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST - elevation myocardial infarction. Circulation. 2006;114:2604 - 10.

[0711] Bovelli D, et al. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v277-82.

[0712] Bullock BP, et al. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137:2968-78.

[0713] Caffes N, et al. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci. 2015;16:4973-84.

[0714] Chaudhuri KR, et al. Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism Relat Disord. 2016;33(Suppl 1):S2-S8.

[0715] Cordiner RLM, Pearson ER. Reflections on the sulfonylurea story: A drug class at risk of extinction or a drug class worth reviving?Diabetes Obes Metab. 2019;21:761-771

[0716] Dae MW,et al.Effect of endovascular cooling on myocardialtemperature,infarct size,and cardiac output in human-sized pigs.Am J PhysiolHeart Circ Physiol.2002;282:H1584-91.

[0717] Dinh QN,et al.Cell-specific mineralocorticoid receptors:futuretherapeutic targets for stroke?Neural Regen Res.2016;11(8):1230-1.

[0718] Garber AJ,et al.CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OFCLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THECOMPREHENSIVE TYPE 2DIABETES MANAGEMENT ALGORITHM-2019EXECUTIVESUMMARY.Endocr Pract.2019;25:69-100.

[0719] R,et al.Exendin-4is a high potency agonist and truncatedexendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.J.Biol.Chem.268:19650-19655.

[0720] M,et al.Mild hypothermia reduces acute mortality and improveshemodynamic outcome in a cardiogenic shock pig model.Resuscitation.2010;81:1190-6.

[0721] Gouzoulis-Mayfrank E,Daumann J.Neurotoxicity of drugs of abuse--thecase of methylenedioxyamphetamines(MDMA,ecstasy),and amphetamines.DialoguesClin Neurosci.2009;11:305-17.

[0722] Gribble FM,Reimann F.Sulfonylurea action revisited:the post-cloningera.Diabetologia.2003;46:875-891.

[0723] Hambrock A,et al.Resveratrol binds to the sulfonylurea receptor(SUR)and induces apoptosis in a SUR subtype-specific manner.J Biol Chem.2007;282:3347-56.

[0724] Hemphill JC 3rd,et al.Guidelines for the management of spontaneousintracerebral hemorrhage:a guideline for healthcare professionals from theAmerican Heart Association / American Stroke Association.Stroke.2015;46:2032-2060.

[0725] Hochman JS,et al.Early revascularization in acute myocardialinfarction complicated by cardiogenic shock.SHOCK Investigators.Should WeEmergently Revascularize Occluded Coronaries for Cardiogenic Shock.N Engl JMed.1999;341:625-34.

[0726] Holmes DR Jr,et al.Contemporary reperfusion therapy for cardiogenicshock:the GUSTO-I trial experience.The GUSTO-I Investigators.GlobalUtilization of Streptokinase and Tissue Plasminogen Activator for OccludedCoronary Arteries.J Am Coll Cardiol.1995;26:668-74.

[0727] Huang K,et al.Exploratory Analysis of Oral Glibenclamide in AcuteIschemic Stroke.Acta Neurol Scand.2019.5.29;doi:10.1111 / ane.13134.

[0728] Inzucchi SE,et al.Management of hyperglycemia in type 2diabetes,2015:a patient-centered approach:update to a position statement of the AmericanDiabetes Association and the European Association for the Study ofDiabetes.Diabetes Care.2015;38:140-9.

[0729] Jiang B,et al.Role of Glibenclamide in Brain Injury AfterIntracerebral Hemorrhage.Transl Stroke Res.2017;8:183-193.

[0730] Johnson CO,et al.Global,regional,and national burden of stroke,1990-2016:a systematic analysis for the Global Burden of Disease Study 2016.LancetNeurol.2019;18:439-458.

[0731] Jorm AF,Korten AE,Henderson AS(1987.11)."The prevalence of dementia:aquantitative integration of the literature".Acta Psychiatrica Scandinavica.76(5):465-79.doi:10.1111 / j.1600-0447.1987.tb02906.x.PMID 3324647.

[0732] Kern KB.Usefulness of cardiac arrest centers-extending lifesavingpost-resuscitation therapies:the Arizona experience.Circ J.2015;79(6):1156-63.

[0733] Kim JY,et al.Multilayer nanoparticles for sustained delivery ofexenatide to treat type 2diabetes mellitus.Biomaterials.2013;34:8444-9.

[0734] King ZA, et al. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date. Drug Des Devel Ther. 2018;12:2539 - 2552.

[0735] Kronick SL, et al. Part 4: Systems of Care and Continuous Quality Improvement: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S397 - 413.

[0736] Kunte H, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol. 2012;72:799 - 806.

[0737] Hyun Joon Lee, et al. (Citicoline Protects Against Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion, J Clin Neurol. 2009;5(1):33–38.

[0738] Lopez MS, et al. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int. 2015;89:75 - 82.

[0739] Marin B,et al.Variation in worldwide incidence of amyotrophic lateralsclerosis:a meta-analysis.Int J Epidemiol 2017;46:57-74.

[0740] Mehta RI,et al.Sur1-Trpm4 Cation Channel Expression in Human CerebralInfarcts.J Neuropathol Exp Neurol.2015;74:835-49.

[0741] Nishida H,et al.Glimepiride treatment upon reperfusion limits infarctsize via the phosphatidylinositol 3-kinase / Akt pathway in rabbit hearts.JPharmacol Sci.2009;109:251-6.

[0742] T,et al.Effects of glucagon-like peptide-1 on endothelialfunction in type 2 diabetes patients with stable coronary artery disease.Am JPhysiol Endocrinol Metab.2004;287:E1209-15.

[0743] Okuda M.A multidisciplinary overview of cardiogenic shock.Shock.2006;25:557-70.

[0744] Patel AD,et al.Glibenclamide reduces hippocampal injury and preservesrapid spatial learning in a model of traumatic brain injury.J Neuropathol ExpNeurol.2010;69:1177-90.

[0745] Patel RAG, et al. Neuroprotection in the Treatment of Acute Ischemic Stroke. Prog Cardiovasc Dis. 2017;59:542 - 548.

[0746] Patel RD, Saver JL. Evolution of reperfusion therapies for acute brain and acute myocardial ischemia: a systematic, comparative analysis. Stroke. 2013;44:94 - 8.

[0747] Powers WJ, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association / American Stroke Association. Stroke. 2018;49:e46 - e99.

[0748] Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB (2007). "Prevalence of dementia in the United States: the aging, demographics, and memory study". Neuroepidemiology. 29(1–2):125 - 32. doi:10.1159 / 000109998. PMC2705925. PMID 17975326.

[0749] Proks P, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):S368 - 76.

[0750] Rawlins MD.The Prevalence of Huntington'sDisease.Neuroepidemiology.2016;46:144-53.

[0751] Roth GA,et al.Global,regional,and national age-sex-specific mortalityfor 282causes of death in 195countries and territories,1980-2017:a systematicanalysis for the Global Burden of Disease Study 2017.Lancet.2018;392:1736-1788.

[0752] Savitz SI,et al.Reconsidering Neuroprotection in the ReperfusionEra.Stroke.2017;48:3413-3419.

[0753] Schmid-Elsaesser R,et al.A critical reevaluation of the intraluminalthread model of focal cerebral ischemia:evidence of inadvertent prematurereperfusion and subarachnoid hemorrhage in rats by laser-Dopplerflowmetry.Stroke.1998;29:2162-70.

[0754] Simard JM,et al.Newly expressed SUR1-regulated NC(Ca-ATP)channelmediates cerebral edema after ischemic stroke.Nat Med.2006;12:433-40.

[0755] Simard, JM, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism. 2009;29;317-330.

[0756] Simard JM, et al. Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke. Transl Stroke Res. 2012;3:286-95.

[0757] Simard, JM, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia Ann. N.Y. Acad. Sci. 2012, 1268, 95-107.

[0758] Sola D, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840-8.

[0759] Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002;144(5 suppl):S2-7.

[0760] Tan F, et al. Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats. Brain Res. 2014;1560:83-90.

[0761] Tosun C,et al.Inhibition of the Sur1-Trpm4 channel reducesneuroinflammation and cognitive impairment in subarachnoidhemorrhage.Stroke.2013;44:3522-8.

[0762] Wilkinson CM,et al.Glibenclamide,a Sur1-Trpm4 antagonist,does notimprove outcome after collagenase-induced intracerebral hemorrhage.PLoSOne.2019;14:e0215952.

[0763] Woo SK,et al.The sulfonylurea receptor 1(Sur1)-transient receptorpotential melastatin 4(Trpm4)channel.J Biol Chem.2013;288:3655-67.

[0764] Xu ZM,et al.Glibenclamide Attenuates Blood-Brain Barrier Disruptionin Adult Mice after Traumatic Brain Injury.J Neurotrauma.2017;34:925-933.

[0765] Xu F,et al.Glibenclamide ameliorates the disrupted blood-brainbarrier in experimental intracerebral hemorrhage by inhibiting the activationof NLRP3 inflammasome.Brain Behav.2019;9:e01254.

[0766] Zannad F,Radauceanu A.Effect of MR blockade on collagen formation andcardiovascular disease with a specific emphasis on heart failure.Heart FailRev.2005;10:71-8.

[0767] Zhang G,et al.A Protective Role of Glibenclamide in Inflammation-Associated Injury.Mediators Inflamm.2017;2017:3578702.

[0768] Zhu S, et al. Glibenclamide Enhances the Therapeutic Benefits of EarlyHypothermia after Severe Stroke in Rats. Aging Dis. 2018; 9:685-695.

[0769] Table 1: Effects of exenatide, potassium canrenoate and glibenclamide on cerebral infarction at day 7 and on modified neurological severity score (NSS) at days 2 and 7 after repeated administration (7 days) as monotherapy in a rat model of transient middle cerebral artery occlusion. The percentage change of the effect in the treatment group compared to the effect in the control group, as well as the statistical comparison results of the effect of the treatment group compared to the control group are shown in brackets (NS: statistically not significant; *: P < 0.05; **: P < 0.01; ***: P < 0.001)

[0770]

[0771] Table 2: Effects of exenatide, potassium canrenoate and glibenclamide on cerebral infarction on day 7 and on modified neurological severity score (NSS) on days 2 and 7 after repeated administration (7 days) as dual or triple combinations in a rat model of transient middle cerebral artery occlusion. The percentage change of the effect in the treatment group compared to the effect in the control group, as well as the statistical comparison results of the effect of the treatment group compared to the control group are shown in brackets (NS: statistically not significant; *: P < 0.05; **: P < 0.01; ***: P < 0.001)

[0772]

Claims

1. A combination comprising: (a) a sulfonylurea which is glibenclamide; and (b) Aldosterone antagonist, which is potassium canrenoate.

2. The combination according to claim 1, wherein the combination further comprises an insulin regulator, which is exenatide or a pharmaceutically acceptable salt thereof.

3. The combination according to claim 1 or claim 2, comprising at least one other active pharmaceutical ingredient (API) selected from beta blockers, renin-angiotensin inhibitors, HMG-CoA reductase inhibitors, platelet activation or aggregation inhibitors, phosphodiesterase-3 inhibitors, calcium sensitizers, antioxidants and anti-inflammatory agents.

4. A pharmaceutical composition comprising the combination according to claim 1 or claim 2 and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable excipient is a diluent.

6. The pharmaceutical composition according to claim 4, which is in a form suitable for parenteral administration.

7. The pharmaceutical composition according to claim 6, wherein the parenteral administration is intravenous, intramuscular or subcutaneous administration.

8. The pharmaceutical composition according to claim 6, which is in a form suitable for oral administration.

9. A pharmaceutical product comprising: (a) a sulfonylurea which is glibenclamide; and (b) Aldosterone antagonist, which is potassium canrenoate.

10. The pharmaceutical product according to claim 9, wherein the pharmaceutical product further comprises an insulin regulator, which is exenatide or a pharmaceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Process for isolating rubbers

    EP0002015A1

  • Anodes for electrochemical purposes

    EP0002017A1

  • Combination

    US10172914B2

  • Peg conjugates of exenatide

    WO2013059323A1

  • combination

    WO2017077378A1